WO2006036278A2 - THERAPEUTIC AGENTS TARGETING THE NCCa-ATP CHANNEL AND METHODS OF USE THEREOF - Google Patents
THERAPEUTIC AGENTS TARGETING THE NCCa-ATP CHANNEL AND METHODS OF USE THEREOF Download PDFInfo
- Publication number
- WO2006036278A2 WO2006036278A2 PCT/US2005/026455 US2005026455W WO2006036278A2 WO 2006036278 A2 WO2006036278 A2 WO 2006036278A2 US 2005026455 W US2005026455 W US 2005026455W WO 2006036278 A2 WO2006036278 A2 WO 2006036278A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- surl
- cell
- subject
- channel
- antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A61K38/166—Streptokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
Definitions
- the present invention is directed to fields of cell biology, physiology and medicine. More specifically, the present invention addresses novel methods of treating a patient comprising administering a therapeutic compound that targets a unique non-selective cation channel activated by intracellular calcium and blocked by intracellular ATP (NCc a -ATP channel).
- the therapeutic compound is an agonist, and uses thereof in therapies, such as cancer therapies, benefiting from death of neuronal cells.
- the therapeutic compound is an antagonist, and uses thereof in therapies, such as treatment of cerebral ischemia or edema, benefiting from blocking and/or inhibiting the NCc a - A T P channel.
- Compositions comprising agonists and/or antagonists of the NCc a -ATP channel are also contemplated.
- NCc a -A TP channel A unique non-selective monovalent cationic ATP-senstive channel (NCc a -A TP channel) was identified first in native reactive astrocytes (NRAs) and later, as described herein, in neurons and capillary endothelial cells after stroke or traumatic brain injury (See, International application WO 03/079987 to Simard et al, and Chen and Simard, 2001, each incorporated by reference herein in its entirety).
- the NCc a A TP channel is thought to be a heteromultimer structure comprised of sulfonylurea receptor type 1 (SURl) regulatory subunits and pore-forming subunits, similar to the K A ⁇ p channel in pancreatic ⁇ cells (Chen et al, 2003).
- SURl sulfonylurea receptor type 1
- the pore-forming subunits of the NCc a -ATP channel remain uncharacterized.
- SUR imparts sensitivity to antidiabetic sulfonylureas such as glibenclamide and tolbutamide, and is responsible for activation by a chemically diverse group of agents termed "K + channel openers" such as diazoxide, pinacidil and cromakalin (Aguilar-Bryan et al, 1995; Inagaki et al, 1996; Isomoto et al, 1996; Nichols et al, 1996; Shyng et al, 1997).
- K + channel openers such as diazoxide, pinacidil and cromakalin
- the KA TP channel in pancreatic ⁇ cells is formed from SURl linked with Kir6.2, whereas the cardiac and smooth muscle K ATP channels are formed from SUR2A and SUR2B linked with Kir6.2 and Kir ⁇ .l, respectively (Fujita et al, 2000).
- the NCca-ATP channel is also sensitive to sulfonylurea compounds.
- the NCc a -ATP channel conducts sodium ions, potassium ions, cesium ions and other monovalent cations with near equal facility (Chen and Simard, 2001) suggesting further that the characterization, and consequently the affinity to certain compounds, of the NCc a -ATP channel differs from the KA T P channel.
- NCc a - ATP channel expressed and found in astrocytes differs physiologically from the other channels with respect to calcium sensitivity and adenine nucleotide sensitivity (Chen et al, 2001).
- the gliotic capsule that forms around a "foreign body" in the brain is an important, albeit neglected, biological system.
- the gliotic capsule represents the response of the brain to an injurious stimulus — an attempt by the brain to wall off, isolate, dispose of, and otherwise protect itself from the foreign body.
- the gliotic capsule forms a potentially harmful mass of tissue from which originates edema fluid that contributes to brain swelling, and whose constituent cells undergo cytotoxic edema, which adds further to brain swelling.
- the gliotic capsule protects foreign cells from immunologic surveillance.
- gliotic capsule The essential elements involved in formation of a gliotic capsule appear to be uniform in many types of CNS pathology, be it a traumatically implanted foreign body, a metastatic tumor, a brain abscess, or infarcted necrotic tissue following a stroke.
- microglia and astrocytes become activated near the site of injury, with large, stellate-shaped GFAP-positive reactive astrocytes forming the most prominent cellular component of the response.
- the foreign nature of the entity is recognized, and the response is initiated to surround and contain it.
- the concept of "foreign body" encompasses a large variety of pathological conditions, the responses in most cases bear a great deal of similarity to one another.
- the gliotic capsule forms a potentially harmful mass of tissue that contributes to brain swelling and mass effect, and that may shelter foreign cells from surveillance by the immune system.
- Applicants are the first to determine that, in a variety pathological conditions in both rats and humans, reactive astrocytes (Rl astrocytes) in the inner zone of the gliotic capsule express a novel SURl -regulated cation channel, the NCc a - ATP channel, and that this channel directly controls cell viability: opening the channel is associated with necrotic cell death and closing the channel is associated with protection from cell death induced by energy (ATP) depletion.
- Reactive astrocytes Rl astrocytes
- Brain metastasis is an important cause of morbidity and mortality in cancer patients. Because most of these patients die of systemic disease, the primary therapeutic goal is often simply to improve the quality of life. Conventional therapy for brain metastases is usually whole-brain irradiation. Chemotherapy may result in regression of brain metastases in chemosensitive tumors, but overall, results of adjunctive therapy including chemotherapy and immunotherapy are disappointing.
- BBB blood- brain barrier
- TTB rumor-brain barrier
- metastatic cancers of the brain induce a significant astrocytic reaction, resulting in formation of a gliotic capsule.
- the gliotic capsule that forms around a metastatic tumor represents the response of the brain to an injurious stimulus — an attempt by the brain to wall off, isolate, dispose of, and otherwise protect itself from the metastatic tumor.
- the gliotic capsule also functions as a barrier that protects the metastatic tumor from immunologic surveillance and therapeutic targeting.
- BBB blood brain barrier
- Monotherapies with chemotherapeutic agents tends not to be very effective because conventional chemotherapeutic agents tend not to reach portions of the CNS in effective amounts, primarily because of the blood-brain barrier (BBB).
- BBB blood-brain barrier
- etoposide and actinomycin D two commonly used oncology agents that inhibit topoisomerase II, fail to cross the blood-brain barrier in useful amounts.
- Applicants are the first to determine that the inner zone of the gliotic capsule is populated by Rl astrocytes expressing the NCc a -ATP channel, and selectively killing the astrocytes expressing the NCc a -A ⁇ p channel disrupts the TBB, causing migration of leukocytes across the TBB.
- the present invention relates to a unique non-selective cation channel activated by intracellular calcium and blocked by intracellular ATP (NCc a -ATP channel) that can be expressed in neuronal cells, neuroglia cells (e.g., astrocyte, ependymal cell, oligodentrocyte and microglia) or neural endothelial cells (e.g., capillary endothelial cells) in which the cells have been or are exposed to a traumatic insult, for example, an acute neuronal insult (e.g., hypoxia, ischemia, cerebral edema or cell swelling), toxic compounds or metabolites, an acute injury, cancer, brain abscess, etc.
- Nc a -ATP channel intracellular calcium and blocked by intracellular ATP
- a traumatic insult for example, an acute neuronal insult (e.g., hypoxia, ischemia, cerebral edema or cell swelling), toxic compounds or metabolites, an acute injury, cancer, brain abscess
- the present invention relates to the regulation and/or modulation of this NCc a -AT P channel and how its modulation can be used to treat various diseases and/or conditions, for example hyperproliferative diseases and acute neuronal insults (e.g., stroke, an ischemic/hypoxic insult). Yet further, the present invention relates to the regulation and/or modulation of this NCc a -ATP channel and its role in maintaining or disrupting the integrity of the gliotic capsule. The modulation and/or regulation of the channel results from administration of an activator or agonist of the channel or an antagonist or inhibitor of the channel.
- a composition (an antagonist or inhibitor) is administered to block or inhibit the channel to prevent cell death, for example to treat cerebral edema that results from ischemia due to tissue trauma or to increased tissue pressure.
- the channel is blocked to prevent or reduce or modulate depolarization of the cells.
- it is desirable to open or activate the channel by administering an agonist or activator compound to cause cell depolarization resulting in cell death of the cancer cells or hyperproliferative cells.
- composition(s) of the present invention may be delivered alimentary or parenterally.
- alimentary administration include, but are not limited to orally, buccally, rectally, or sublingually.
- Parenteral administration can include, but are not limited to intramuscularly, subcutaneously, intraperitoneally, intravenously, intratumorally, intraarterially, intraventricularly, intracavity, intravesical, intrathecal, or intrapleural.
- Other modes of administration may also include topically, mucosally, transdermally, direct injection into the brain parenchyma.
- An effective amount of an agonist or antagonist of NCc a -ATP channel that may be administered to a cell includes a dose of about 0.0001 nM to about 2000 ⁇ M. More specifically, doses of an agonist to be administered are from about 0.01 nM to about 2000 ⁇ M; about 0.01 ⁇ M to about 0.05 ⁇ M; about 0.05 ⁇ M to about 1.0 ⁇ M; about 1.0 ⁇ M to about 1.5 ⁇ M; about 1.5 ⁇ M to about 2.0 ⁇ M; about 2.0 ⁇ M to about 3.0 ⁇ M; about 3.0 ⁇ M to about 4.0 ⁇ M; about 4.0 ⁇ M to about 5.0 ⁇ M; about 5.0 ⁇ M to about 10 ⁇ M; about 10 ⁇ M to about 50 ⁇ M; about 50 ⁇ M to about 100 ⁇ M; about 100 ⁇ M to about 200 ⁇ M; about 200 ⁇ M to about 300 ⁇ M; about 300 ⁇ M to about 500 ⁇ M; about 500 ⁇ M to about 1000 ⁇ M; about 1000 ⁇ M;
- an effective amount of an agonist and/or antagonist of the NC Ca-ATP channel or related-compounds thereof as a treatment varies depending upon the host treated and the particular mode of administration.
- the dose range of the agonist and/or antagonist of the NCc a- ATP channel or related-compounds thereof will be about 0.01 ⁇ g/kg body weight to about 20,000 ⁇ g/kg body weight.
- body weight is applicable when an animal is being treated. When isolated cells are being treated, “ body weight " as used herein should read to mean “total cell body weight ". The term “total body weight" may be used to apply to both isolated cell and animal treatment.
- a variety of different dosage levels will be of use, for example, 0.0001 ⁇ g/kg, 0.0002 ⁇ g/kg, 0.0003 ⁇ g/kg, 0.0004 ⁇ g/kg, 0.005 ⁇ g/kg, 0.0007 ⁇ g/kg, 0.001 ⁇ g/kg, 0.1 ⁇ g/kg, 1.0 ⁇ g/kg, 1.5 ⁇ g/kg, 2.0 ⁇ g/kg, 5.0 ⁇ g/kg, 10.0 ⁇ g/kg, 15.0 ⁇ g/kg, 30.0 ⁇ g/kg, 50 ⁇ g/kg, 75 ⁇ g/kg, 80 ⁇ g/kg, 90 ⁇ g/kg, 100 ⁇ g/kg, 120 ⁇ g/kg, 140 ⁇ g/kg, 150 ⁇ g/kg, 160 ⁇ g/kg, 180 ⁇ g/kg, 200 ⁇ g/kg, 225 ⁇ g/kg, 250 ⁇ g/kg, 275 ⁇ g/kg, 300 ⁇ g/kg,
- NCc a - AT P channel is blocked by antagonists of type 1 sulfonylurea receptor (SURl) and opened by SURl activators. More specifically, the antagonists of type 1 sulfonylurea receptor (SURl) include blockers of K ATP channels and the SURl activators include activators of KATP channels.
- SURl type 1 sulfonylurea receptor
- the NCca-ATP channel of the present invention has a single-channel conductance to potassium ion (K + ) between 20 and 50 pS.
- the NCc a - ATP channel is also stimulated by Ca 2+ on the cytoplasmic side of the cell membrane in a physiological concentration range, where concentration range is from 10 "8 to 10 '5 M.
- the NCc a - A TP channel is also inhibited by cytoplasmic ATP in a physiological concentration range, where the concentration range is from 10 "1 to 10 M.
- NCc a - ATP channel is also permeable to the following cations; K + , Cs + , Li + , Na + ; to the extent that the permeability ratio between any two of the cations is greater than 0.5 and less than 2.
- Certain embodiments of the present invention comprise a method of treating a hyperproliferative disease by administering to a subject an amount of a compound effective to activate a NCc a - AT P channel in a neuronal cell or a neuroglia cell or a neural endothelial cell or a combination thereof.
- the activation of the channel results in an influx of sodium ions (Na + ) causing depolarization of the cell.
- the influx of Na + alters the osmotic gradient causing an influx of water into the cell which leads to cytotoxic edema ultimately resulting in necrotic cell death.
- the hyperproliferative disease is a tumor, for example, a benign or malignant tumor. More specifically, the tumor is a neuroma or glioma. Still further, the tumor can originate from a primary brain tumor or metastatic brain tumor. Gliomas can include, but are not limited to astocytoma, brain stem glioma, ependymomas, optic nerve glioma, and oligodendroglioma.
- the tumor may also be gliobastoma, medulloblastoma, papilloma of choroid plexus, metastases, meningioma, pituitary adenoma, Schwannoma, lymphoma, congenital tumors, neurosarcoma, neurofibromatosis, neuroblastoma, craniopharyngioma, pineal region tumors or primitive neuroectodermal tumors.
- the activator compound or agonist can be a type 1 sulfonylurea receptor agonist.
- agonists that can be used in the present invention include, but are not limited to agonist of SURl, for example, diazoxide, pinacidil, P 1075, and cromakalin.
- agonists can include, but are not limited to diazoxide derivatives, for example 3-isopro ⁇ ylamino- 7-methoxy-4H-l,2,4-benzothiadiazine 1,1-dioxide (NNC 55-9216), 6,7-dichloro-3- isopropylamino-4H-l,2,4-benzothiadiazine 1,1-dioxide (BPDZ 154), 7-chloro-3-isopropylamino- 4H-l,2,4-benzothiadiazine 1,1-dioxide (BPDZ 73), 6-Chloro-3-isopropylamino-4 H-thieno[3,2- e]-l,2,4-thiadiazine 1,1-dioxide (NNC 55-0118)4, 6-chloro-3-(l-methylcyclopropyl)amino-4 H- thieno[3,2-e]-l,2,4-thiadiazine 1,1-dioxide (NN414),
- the method comprises administering to the subject an anti-cancer therapy in combination with the activator compound that activates or stimulates or opens the NCc a - ATP channel.
- the anti-cancer or anti-tumor therapy is chemotherapy, radiotherapy, immunotherapy, surgery or a combination thereof.
- Another embodiment of the present invention comprises a method of disrupting the integrity of the tumor-brain barrier surrounding a tumor in the brain of a subject comprising administering to the subject a compound effective to activate a NCc a - ATP channel in a neuronal cell, or a neuroglia cell, a neural endothelial cell or a combination thereof.
- This method can further comprise administering to the subject an anti-cancer therapy, wherein the anti-cancer or anti-tumor therapy is chemotherapy, radiotherapy, immunotherapy, surgery or a combination thereof.
- another embodiment of the present invention comprises a method of inducing cell death of a neuronal or a neuralgia cell or a neural endothelial cell comprising administering to the cell a compound effective to activate a NCc a-ATP channel in the cell.
- Activation of the NCc a - ATP channel results in an influx of sodium ions (Na ) causing depolarization of the cell.
- Na + sodium ions
- the influx of Na + alters the osmotic gradient causing an influx of water into the cell which leads to cytotoxic edema ultimately resulting in necrotic cell death.
- another embodiment of the present invention comprises a pharmaceutical composition
- a pharmaceutical composition comprising a thrombolytic agent (e.g., tissue plasminogen activator (tPA), urokinase, prourokinase, streptokinase, anistreplase, reteplase, tenecteplase), an anticoagulant or antiplatelet (e.g., aspirin, warfarin or Coumadin), statins, diuretics, vasodilators, mannitol, diazoixde or similar compounds that stimulates or promotes ischemic precondition or a pharmaceutically acceptable salt thereof and a compound that inhibits a NCc a - A ⁇ p channel or a pharmaceutically acceptable salt thereof.
- a thrombolytic agent e.g., tissue plasminogen activator (tPA), urokinase, prourokinase, streptokinase, anistreplase, reteplase,
- This pharmaceutical composition can be considered neuroprotective.
- the pharmaceutical composition comprising a combination of the thrombolytic agent and a compound that inhibits a NCc a - ATP channel is neuroprotective because it increases the therapeutic window of for the administration of the thrombolytic agent by several hours, for example the therapeutic window for administration of thrombolytic agents may be increased by several hours (4-8 hrs) by co-administering antagonist of the NCc a - ATP channel.
- the channel can be inhibited by an NCc a -A T P channel inhibitor, an NCc aA T P channel blocker, a type 1 sulfonylurea receptor (SURl) antagonist, SURl inhibitor, or a compound capable of reducing the magnitude of membrane current through the channel.
- an NCc a -A T P channel inhibitor an NCc aA T P channel blocker, a type 1 sulfonylurea receptor (SURl) antagonist, SURl inhibitor, or a compound capable of reducing the magnitude of membrane current through the channel.
- SURl type 1 sulfonylurea receptor
- the SURl antagonist is selected from the group consisting of glibenclamide, tolbutamide, repaglinide, nateglinide, meglitinide, midaglizole, LY397364, LY389382, glyclazide, glimepiride, estrogen, estrogen related-compounds (estradiol, estrone, estriol, genistein, non-steroidal estrogen (e.g., diethystilbestrol), phytoestrogen (e.g., coumestrol), zearalenone, etc.), and compounds known to inhibit or block KA TP channels.
- MgADP can also be used to inhibit the channel.
- KA TP channels include, but are not limited to tolbutamide, glyburide (l[p-2[5-chloro-O- anisamido)ethyl] phenyl] sulfonyl] -3-cyclohexyl-3-urea); chlopropamide (l-[[(p- chlorophenyl)sulfonyl]-3-pro ⁇ ylurea; glipizide (l-cyclohexyl-3[[p-[2(5-methylpyrazine carboxamido)ethyl] phenyl] sulfonyl] urea); or tolazamide(benzenesulfonamide-N-[[(hexahydro- lH-azepin-lyl)amino] carbonyl] -4-methyl).
- Another embodiment of the present invention comprises a composition comprising a membrane preparation derived from a neural endothelial cell expressing a NCc a - A ⁇ p channel, wherein channel is blocked by antagonists of type 1 sulfonylurea receptor (SURl) and opened by SURl activators. More specifically, the channel has the following characteristics: (a) it is a 35 pS type channel; (b) it is stimulated by cytoplasmic Ca 2+ in the concentration range from about 10 " to about 10 M; (c) it opens when cytoplasmic ATP is less than about 0.8 ⁇ M; and (d) it is permeable to the monovalent cations K + , Cs + , Li + and Na + .
- SURl type 1 sulfonylurea receptor
- the compound that inhibits the NCc a - A ⁇ p channel can be administered in combination with a thrombolytic agent (e.g., tissue plasminogen activator (tPA), urokinase, prourokinase, streptokinase, anistreplase, reteplase, tenecteplase), an anticoagulant or antiplatelet (e.g., aspirin, warfarin or Coumadin), statins, diuretics, vasodilators (e.g., nitroglycerin), mannitol, diazoixde or similar compounds that stimulates or promotes ischemic precondition.
- a thrombolytic agent e.g., tissue plasminogen activator (tPA), urokinase, prourokinase, streptokinase, anistreplase, reteplase, tenecteplase
- an anticoagulant or antiplatelet e
- another embodiment comprises a method of treating an acute cerebral ischemia in a subject comprising administering to a subject an amount of a thrombolytic agent or a pharmaceutically acceptable salt thereof in combination with an amount of a compound that inhibits a NCc a -A T P channel or a pharmaceutically acceptable salt thereof.
- the thrombolytic agent is a tissue plasminogen activator (tPA), urokinase, prourokinase, streptokinase, anistreplase, reteplase, tenecteplase or any combination thereof.
- tPA tissue plasminogen activator
- the SURl antagonist can be administered by any standard parenteral or alimentary route, for example the SURl antagonist may be administered as a bolus injection or as an infusion or a combination thereof.
- the channel is expressed on neuronal cells, neuroglia cells, neural epithelial cells or a combination thereof.
- the inhibitor blocks the influx of Na + into the cells thereby preventing depolarization of the cells. Inhibition of the influx of Na + into the cells thereby prevents cytotoxic edema and reduces hemorrhagic conversion. Thus, this treatment reduces cell death or necrotic death of neuronal and/or neural endothelial cells.
- the amount of the SURl antagonist administered to the subject is in the range of about 0.0001 ⁇ g/kg/day to about 20 mg/kg/day, about O.Ol ⁇ g/kg/day to about 100 ⁇ g/kg/day, or about 100 ⁇ g/kg/day to about 20 mg/kg/day.
- the SURl antagonist may be administered to the subject in the from of a treatment in which the treatment may comprise the amount of the SURl antagonist or the dose of the SURl antagonist that is administered per day (1, 2, 3, 4, etc.), week (1, 2, 3, 4, 5, etc.), month (1, 2, 3, 4, 5, etc.), etc.
- Treatments may be administered such that the amount of SURl antagonist administered to the subject is in the range of about 0.0001 ⁇ g/kg/treatment to about 20 mg/kg/treatment, about 0.01 ⁇ g/kg/treatment to about 100 ⁇ g/kg/treatment, or about 100 ⁇ g/kg/treatment to about 20 nig/kg/treatment.
- Another embodiment of the present invention comprises a method of reducing mortality of a subject suffering from a stroke comprising administering to the subject a compound effective to inhibit a NCca- AT P channel in a neuronal cell, a neuroglia cell, a neural endothelial cell or a combination thereof.
- the compound reduces stroke size and reduces edema located in the peri-infarct tissue.
- the compound can be administered alimentary (e.g., orally, buccally, rectally or sublingually) or parenterally (e.g., intravenously, intraderrnally, intramuscularly, intraarterially, intrathecally, subcutaneously, intraperitoneally, intraventricularly) and/or topically (e.g., transdermally), mucosally, or by direct injection into the brain parenchyma.
- alimentary e.g., orally, buccally, rectally or sublingually
- parenterally e.g., intravenously, intraderrnally, intramuscularly, intraarterially, intrathecally, subcutaneously, intraperitoneally, intraventricularly
- topically e.g., transdermally
- another embodiment comprises a method of reducing edema in a peri-infarct tissue area of a subject comprising administering to the subject a compound effective to inhibit a NCc a - A TP channel in a neuronal cell, a neuroglia cell, an endothelium cell or a combination thereof.
- Further embodiments comprises a method of treating a subject at risk for developing a stroke comprising administering to the subject a compound effective to inhibit a NCc a - A ⁇ p channel in neuronal cell, a neuroglia cell, a neural endothelial cell or a combination thereof.
- the subject is undergoing treatment for a cardiac condition, thus the condition increases the subjects risk for developing a stroke.
- the treatment may comprise the use of thrombolytic agents to treat myocardial infarctions.
- the subject may be at risk for developing a stroke because the subject suffers from atrial fibrillation or a clotting disorder.
- Other subjects that are at risk for developing a stroke include subjects that are at risk of developing pulmonary emboli, subjects undergoing surgery (e.g., vascular surgery or neurological surgery), or subjects undergoing treatments that increase their risk for developing a stroke, for example, the treatment may comprise cerebral/endovascular treatment, angiography or stent placement.
- Another embodiment of the present invention comprises a method of treating a subject at risk for developing cerebral edema comprising administering to the subject a compound effective to inhibit a NCc a -ATP channel in a neuronal cell, a neuroglia cell, a neural endothelial cell or a combination thereof.
- the subject at risk may be suffering from an arterior- venous malformation, or a mass-occupying lesion (e.g., hematoma) or may be involved in activities that have an increased risk of brain trauma.
- another embodiment of the present invention comprises a method of maintaining the integrity of the gliotic capsule surrounding brain abscess of a subject comprising administering to the subject a compound effective to inhibit and/or block a NCc a - ATP channel in a neuronal cell, or a neuroglia cell, a neural endothelial cell or a combination thereof.
- another method of the present invention comprises a method of diagnosing neuronal cell edema and/or cytotoxic damage in the brain comprising: labeling an antagonist of SURl; administering the labeled antagonist of SURl to a subject; measuring the levels of labeled antagonist of SURl in the brain of the subject, wherein the presence of labeled antagonist of SURl indicates neuronal cell edema and/or cytotoxic damage in the brain.
- Another method of the present invention comprise determining the boundaries of a brain tumor comprising: labeling an antagonist of SURl; administering the labeled antagonist of SURl to a subject; visualizing the labeled antagonist of SURl in the brain of the subject, wherein the presence of labeled antagonist of SURl indicates the boundaries of the brain tumor, for example, a metastatic tumor, hi certain embodiments, the step of visualizing is performed using by using positron emission topography (PET) scans.
- PET positron emission topography
- the methods can comprise a method of determining the penumbra following a stroke comprising: labeling an antagonist of SURl; administering the labeled antagonist of SURl to a subject; visualizing the labeled antagonist of SURl in the brain of the subject, wherein the presence of labeled antagonist of SURl indicates the penumbra.
- the present invention comprises a method monitoring stroke neural disease comprising: labeling an antagonist of SURl; administering the labeled antagonist of SURl to a subject; visualizing the labeled antagonist of SURl in the brain of the subject, wherein the presence of labeled antagonist of SURl indicates the progression of the disease.
- the step is visualizing is performed daily to monitor the progression of the stroke.
- Another embodiment comprises a neuroprotective infusion kit comprising a compound that inhibits a NCc a -ATP channel in a neuronal cell, a neuroglia cell, a neural endothelial cell or a combination thereof and an IV solution.
- the compound and solution are contained within the same container or within different containers. More specifically, the compound is contained within the container of solution.
- the kit may further comprise a neuroprotective bolus kit, wherein the bolus kit comprises a pre-loaded syringe of a compound inhibits a NCc a- A ⁇ p channel in a neuronal cell, a neuroglia cell, a neural endothelial cell or a combination thereof.
- another embodiment comprises a neuroprotective kit comprising a compound that inhibits NCc a - ATP channel in a neuronal cell, a neuroglia cell, an endothelium cell or a combination thereof and a thrombolytic agent (e.g., tPA), an anticoagulant (e.g., warfarin or Coumadin), an antiplatelet (e.g., aspirin), a diuretic (e.g., mannitol), a statin, or a vasodilator (e.g., nitroglycerin).
- a thrombolytic agent e.g., tPA
- an anticoagulant e.g., warfarin or Coumadin
- an antiplatelet e.g., aspirin
- diuretic e.g., mannitol
- statin e.g., a statin
- vasodilator e.g., nitroglycerin
- FIG. 1 shows that addition of exogenous phosphatidylinositol-4,5-bisphosphate (PIP 2 ) causes activation of the NCcaATP channel, despite the presence of ATP in the bath solution.
- PIP 2 exogenous phosphatidylinositol-4,5-bisphosphate
- FIG. 2 shows that the NC Ca- ATP channel in an Rl astrocyte is inhibited by estrogen.
- the ii ⁇ tial portion of the record shows brisk activity from a number of superimposed channels, recorded in a cell attached patch of membrane from an Rl astrocyte obtained from a female.
- Addition of 10 nM estrogen to the bath promptly resulted in strong inhibition of channel activity.
- the mechanism involved is believed to be related to estrogen receptor mediated activation of phospholipase C (PLC), resulting in depletion of PIP 2 from the membrane, and reflecting an apparent increase in affinity for ATP.
- PLC phospholipase C
- FIGS. 3A-3B show Western blots demonstrating that Rl astrocytes from both males and females express estrogen receptors and SURl, a marker of the NCca- ATP channel.
- Cell lysates were obtained from gelatin sponge implants from males (M) and females (F) and studied at two dilutions (4x and Ix), with lysates from uterus used as controls.
- FIG. 3A was developed using antibodies directed against estrogen receptors (ER), demonstrating that both ERa and ER ⁇ are expressed in astrocytes from both genders.
- Western blots showed that SURl is also expressed by cells from both genders, with pancreatic tissue used as control (FIG. 3B).
- FIG. 4 shows that the NCc a -ATP channel in an Rl astrocyte from a male is inhibited by estrogen.
- the initial portion of the record shows brisk activity from a number of superimposed channels, recorded in a cell attached patch of membrane from an Rl astrocyte obtained from a male. Addition of 10 nM estrogen to the bath promptly resulted in strong inhibition of channel activity.
- FIGS 5A-5D shows the gliotic capsule.
- FIG. 5A shows a coronal section of a rat brain sectioned though the site of implantation of a large gelatin sponge; the sponge (innermost dark region) is encapsulated by a gliotic capsule (light area), outside of which is found a region of vasogenic edema (outer dark area), identified by pre-mortem administration of methylene blue.
- FIG. 5B and 5C show low power and high power views, respectively, of the gliotic capsule immunolabeled for GFAP.
- FIG. 5D shows a high power view of GFAP-labeled cells inside of the gelatin sponge implant.
- FIGS. 6A-6H show immunolabeled astrocytes.
- FIGS. 6A, 6C, 6E show freshly- isolated large phase-bright Rl astrocytes immunolabeled for GFAP (FIG. 6C) and vimentin (FIG. 6E).
- FIG. 6B,D,F show freshly-isolated small phase-dark R2 astrocytes immunolabeled for GFAP (FIG. 6D) and vimentin (FIG. 6F).
- FIG. 6G shows primary cultures of astrocytes isolated from a gliotic capsule, with Rl astrocytes developing into large polygonal cells (FIG. 6Gb), and R2 astrocytes developing into small bipolar cells (FIG. 6Ga).
- FIG. 6H shows that R2 astrocytes, but not Rl astrocytes, are labeled with fluorescein tagged chlorotoxin derived from the scorpion, Leiurus quinquestriatus.
- FIGS. 7A-7D show that the inner zone of the gliotic capsule expresses SURl but not SUR2. Immunolabling for SURl (FIG. 7A) showed prominent expression in cells adjacent to the gelatin sponge (gf), whereas immunolabeling for SUR2 showed no expression (FIG. 7B). A single cell enzymatically isolated from a gelatin sponge implant and immunolabeled for SURl is shown (FIG. 7C). FIG. 7D shown RT-PCR for SURl in control insulinoma cells (lane 2) and in isolated Rl astrocytes (lane 3), and for SUR2 in control cardiac cells (lane 4), but not in isolated Rl astrocytes (lane 5).
- FIGS. 8A-8I show various features of the gliotic capsule.
- the gliotic capsule is characterized by GFAP -positive cells that are several cell-layers thick (FIG. 8A). Only the inner zone of the gliotic capsule is hypoxic, as demonstrated by pimonidozole labeling (FIG. 8B) and by immunolabeling for HIFl ⁇ (FIG. 8C). Also, only the inner zone is immunolabeled for SURl (FIG. 8D), and for the tight junction proteins, ZO-I (FIG. 8E) and occludens (FIG. 8F).
- FIGS. 8G-I show that pimonidazole, HIFl ⁇ and occludens all localize to GFAP-positive astrocytes that form the inner zone of the gliotic capsule.
- FIGS. 9A-B show effects of NC Ca -ATP channel inhibition (FIG. 9A) and NC Ca- ATP channel activation (FIG. 9B) on the gliotic capsule.
- Animals with gelatin sponge implants were treated with glibenclamide infusion (FIG. 9A) or diazoxide infusion (FIG. 9B) via osmotic mini-pumps that delivered the compounds directly into the area of the gelatin sponge.
- Immunolabeling for GFAP showed that channel inhibition with glibenclamide resulted in formation of a well defined gliotic capsule (FIG. 9A), whereas channel activation with diazoxide resulted in formation of a broader, ill-defined capsule (FIG. 9B), due to diazoxide-induced necrotic death of inner zone cells.
- FIGS. 10A-B show that infusion of diazoxide into the area around the gelatin sponge resulted in a heavy infiltration of polymorphonuclear leukocytes (PMNs).
- Nuclear labeling with DAPI showed densely packed small cells in the vicinity of the gelatin sponge (FIG. 10A), with immunolabeling using the PMN-specific marker, MMP-8, demonstrating that these cells were PMNs (FIG. 10B). It is believed that the strong inflammatory response represented by the infiltrating PMNs was due to disruption of the barrier between brain and foreign body (gelatin sponge) normally formed by the inner zone of the gliotic capsule.
- FIGS. 1 IA-I IL show that Rl astrocytes in the inner zone of the gliotic capsule typically express SURl, a marker for the NCc a - AT P channel.
- the inner zones of the gliotic capsules in rats with gelatin sponge implants (FIGS. 1 IA-11C), in rats with cerebral abscess (FIGS. 1 ID-I IF), and in humans with metastatic tumor (FIGS. 11 J-I IL) are shown.
- the area of reactive gloss adjacent to a stroke in the rat (FIGS. 11 G- 111) resulting from occlusion of the middle cerebral artery.
- a field of cells is labeled for GFAP and co- labelled for SURl, as indicated. Examples of single cells at high power are also shown for each condition.
- FIGS. 12A-12C shows that stellate astrocytes near the edge of a stroke up- regulate SURl (FIG. 12A), a marker of the NCc a -ATP channel, hi the middle of the stroke, cells with altered morphology including blebbing are also immunolabeled for SURl (FIG. 12B,12C).
- FIGS. 13A-13C show that glibenclamide protects from Na azide-induced channel opening and necrotic cell death.
- FIG. 13 A shows phase contrast images of 4 different freshly isolated Rl astrocytes observed over the course of 30 min each.
- the cell exposed to vehicle solution alone remained phase bright with no pathological deterioration (control).
- the cell depleted of ATP by exposure to Na azide (1 mM) developed progressive blebbing consistent with cytotoxic edema.
- the cell exposed to the NCc a - ATP channel opener, diazoxide developed progressive blebbing consistent with cytotoxic edema.
- the cell exposed to Na azide in the presence of glibenclamide remained phase bright with no pathological deterioration.
- FIGS. 13B and 13C show cell death of isolated Rl astrocytes induced by ATP depletion in vitro.
- Freshly isolated Rl astrocytes were labeled for necrotic death with propidium iodide (PI) (FIG. 13B), or for apoptotic death with annexin V (FIG. 13C), under control conditions, after exposure to Na azide (1 mM), or after exposure to Na azide in the presence of glibenclamide (1 ⁇ M). Exposure to Na azide resulted mostly in necrotic death that was largely prevented by glibenclamide.
- PI propidium iodide
- FIGS. 13C show cell death of isolated Rl astrocytes induced by ATP depletion in vitro.
- Freshly isolated Rl astrocytes were labeled for necrotic death with propidium iodide (PI) (FIG. 13B), or for apoptotic death with annexin V (FIG
- FIG. 14A-14L shows that SURl is up-regulated in MCA stroke.
- Watershed area between MCA-ACA in 3 different animals 8-16 hr after MCA stroke identified by pre-mortem administration of Evans blue and postmortem perfusion with India ink (FIG. 14A), by TTC staining (FIG. 14B) and by immunofluorescence imaging for SURl (FIG. 14C).
- Immunofluorescence images showing SURl at 3 hr in the core of the stroke in cells (FIG. 14D) double-labeled for the neuronal marker, NeuN (FIG. 14E), and showing SURl at 8 hr in the peri- infarct region in cells (FIG.
- FIGS. 15A-15G show that SURl but not Kir ⁇ .l or Kir6.2 is transcriptionally up-regulated in MCA stroke.
- FIGS 16A-16D show patch clamp recordings of NCcaATP channel in neuron-like cells in stroke.
- FIG. 16 A shows phase-contrast image of large neuron-like cells enzymatically isolated from ischemic region 3 hr following MCAO.
- FIG. 16B shows recording of inside-out patch using Cs + as the charge carrier; channel activity was blocked by glibenclamide given as indicated (arrow); a and b show expanded records of the portions indicated.
- FIG. 16C shows recordings at potentials indicated of inside-out patch using K + as the charge carrier; channel activity was blocked by glibenclamide.
- FIG. 16D shows a plot of single channel amplitudes at different voltages showing single channel slope conductance of 34 pS.
- FIGS. 17A-17E show that glibenclamide reduces mortality, edema and stroke size in MCA stroke.
- FIG. 17A Mortality was assessed during 7 days after MCA stroke [double occlusion model with malignant cerebral edema (MCE)] in two treatment groups, each comprised of 19 female and 10 male rats, treated with either saline (empty symbols) or glibenclamide (filled symbols); mortality at 7 days was significantly different. Subgroup analyses for males and females showed similar results, hi FIG.
- 17B edema was assessed 8 hr after MCA stroke (MCE model) in two treatment groups, each comprised of 6 male rats treated with either saline or glibenclamide; tissues were first processed with TTC to allow separation into TTC(+) and TTC(-) portions of the involved hemisphere and contralateral hemisphere, prior to determining wet/dry weights; values in TTC(+) regions were statistically different.
- MCA stroke MCA stroke
- stroke size was assessed 48 hr after MCA stroke [thromboembolic (TE) model] in two treatment groups, each comprised of 10 male rats, treated with either saline or glibenclamide; images of TTC-stained coronal sections following MCA stroke (TE model) in an animal treated with saline (FIG. 17C) and another treated with glibenclamide (FIG. 17D), showing cortical sparing often associated with glibenclamide treatment; values of stroke size, expressed as percent of hemisphere volume (FIG. 17E).
- TE thromboembolic
- FIGS 18A-18D show that tissue distribution of BODIP Y-glibenclamide in MCA stroke, a-c, Fluorescence images of brain sections in an animal 6 hr after MCA stroke (MCE model) and administration of BODIP Y-glibenclamide; fluorescent labeling was evident in cells, microvessels (FIG. 18A) and capillaries (FIG. 18C) from ischemic regions, but not in the contralateral hemisphere (FIG. 18B); the images in (FIGS. 18 A, 18B) are from the same animal, taken with the same exposure time; in (FIG.
- FIGS. 19 A-9H show that glibenclaniide reduces hemorrhagic conversion.
- FIGS 19A-19D are from animals co-treated with saline;
- FIGS. 19E-19H are from animals co-treated with glibenclamide.
- the left column of photographs of coronal sections shows, in rows 1-2 only, intraventricular hemorrhage, plus large areas of hemorrhagic conversion in ischemic cortical/subcortical regions (red areas on the right side of pictures; arrows).
- the right column of photographs of TTC-processed sections from the same animals show the areas of infarction.
- FIGS 20A-20B show zymography showing gelatinase activity of matrix metalloproteinases (MMP' s) in stroke, and absence of direct MMP inhibition by glibenclamide.
- FIG. 2OA shows activation of MMP-9 & MMP-2 in stroke tissue compared to control; activity of recombinant MMP-9 & MMP-2 shown at left.
- FIG. 20B shows gelatinase activity of recombinant enzyme and stroke tissue under control conditions (CTR), in presence of glibenclamide (10 ⁇ M), and in presence of MMP inhibitor ⁇ (300 nM; Calbiochem).
- CTR gelatinase activity of recombinant enzyme and stroke tissue under control conditions
- FIG. 21 shows phase contrast photomicrograph of cerebral capillaries freshly isolated from normal brain, after enzymatic cleaning in preparation for patch clamping.
- FIGS. 22A-22F show that freshly isolated cerebral endothelial and smooth muscle cells are readily distinguished electrophysiologically.
- FIGS. 22 A and 22B show superimposed macroscopic currents recorded during 200 ms depolarizing pulses from -120 mV to +120 mV in 20 mV steps in an endothelial cell (FIG. 22A) and in an elongated smooth muscle cell (FIG. 22B); holding potential, -60 mV; nystatin perforated patch technique; bath solution, standard Krebs with 2 mM Ca 2+ ; pipette solution, 145 niM K + .
- FIGS. 22C and 22D show current- voltage curves computed from average (mean ⁇ SE) currents at the end of 200-ms test pulses recorded in 9 endothelial cells (FIG. 22C) and 7 smooth muscle cells (FIG. 22D); same holding potential, technique and solutions as in FIGS. 22A and 22B.
- FIGS. 22E and 22F show current voltage curves recorded during ramp pulses (0.45 mV/ms, holding potential, -60 mV) in an endothelial cell (FIG. 22E) and in a smooth muscle cell (FIG. 22F); same holding potential, technique and bath solution as in FIGS. 22A and 22B, but with pipette solution containing 145 mM Cs + instead of K + .
- FIG. 23 shows real time RT-PCR showing up-regulation of SURl -mRNA in stroke.
- FIGS. 24A-24E show STJRl knock down (SURlKD) in Rl astrocytes protects from ATP-depletion-induced depolarization.
- FIGS. 24 A and 24B show Western blot (FIG. 24A) and quantification of Western blots (FIG. 24B) of Rl cell lysates confirmed knock down of SURl expression by antisense.
- FIGS. 24C-24E show Na azide caused large depolarizations in cells exposed to SCR-ODN (FIG. 24C, 24E) but little or no depolarization in cells exposed to AS-ODN (FIG. 24D 5 24E).
- FIGS. 25A-25F show transcription factors in stroke.
- the peri-infarct region showed up-regulation of both transcription factors, SpI (FIGS. 25A, 25C) and HIFl ⁇ (FIG. 25B) in neuron-like cells and capillaries, as well as SURl in capillaries (FIG. 25D).
- Control tissues showed little SpI and no HIFl ⁇ (FIGS. 25E and 25F).
- FIGS. 26A-26C show an increase in nuclear localization of the transcription factor, SPl, and SPl co-localization with SURl in stroke.
- Immunofluorescence images showing increase of nuclear SPl labeling in ischemic area 3-hr after MCAO (FIG. 26B), compared to contralateral side (FIG. 26A).
- FIG. 26C double labeling of large neuron-like cell showing nuclear SPl (green) and cytoplasmic /plasmalemmal SURl (red) in the same cell.
- FIGS. 27A-27D show regulation of SURl expression by the transcription factor, HIFl ⁇ .
- FIG. 27A and 27C show Western blot analysis of HIFl ⁇ protein in Rl astrocytes from gelfoam implant model of control (CTR) and HIFl ⁇ knock-down (KD).
- FIG. 27B and 27C show SURl protein in the same cell lysates.
- the term "acute” refers to the onset of a health effect, usually the effect is a rapid onset that is considered brief, not prolonged.
- acute cerebral ischemia refers to a cerebral ischemic event that has a rapid onset and is not prolonged.
- acute cerebral ischemia and “stroke” can be used interchangeably.
- anti-cancer therapy refers to any therapy that destroys a cancer cell and/or a tumor cell, or slows, arrests, or reverses the growth of a cancer cell and/or tumor cell.
- Anti-cancer or anti-tumor therapies include, without limitation, radiation therapy (radiotherapy), chemotherapy, or a combination of these therapies.
- the term "agonist” refers to a biological or chemical agent that combines with a receptor on a cell and initiates the same or equivalent reaction or activity produced by the binding of an endogenous substance.
- the agonist combines, binds, and/or associates with a NCc a -A ⁇ p channel of a neuronal cell, a neuroglial cell, or a neural endothelial cell, such that the NCc a - ATP channel is opened (activated).
- the agonist combines, binds and/or associates with a regulatory subunit of the NCc a - ATP channel, particularly a SURl.
- the agonist combines, binds, and/or associates with a pore-forming subunit of the NCc a -ATP channel, such that the NCc a - A ⁇ p channel is opened (activated).
- agonist and/or activator can be used interchangeably.
- the term "antagonist” refers to a biological or chemical agent that acts within the body to reduce the physiological activity of another chemical or biological substance, rn the present invention, the antagonist blocks, inhibits, reduces and/or decreases the activity of a NCc a - ATP channel of a neuronal cell, a neuroglia cell or a neural endothelial cell (e.g., capillary endothelial cells).
- the antagonist combines, binds, associates with a NCc a - ATP channel of neuronal cell, a neuroglia cell or a neural endothelial cell (e.g., capillary endothelial cells), such that the NC CS -A TP channel is closed (deactivated), meaning reduced biological activity with respect to the biological activity in the diseased state.
- the antagonist combines, binds and/or associates with a regulatory subunit of the NCc a - ATP channel, particularly a SURl.
- the antagonist combines, binds, and/or associates with a pore-forming subunit of the NCc a -ATP channel, such that the NCc a - ATP channel is closed (deactivated).
- the terms antagonist or inhibitor can be used interchangeably.
- brain abscess or “cerebral abscess” refer to a circumscribed collection of purulent exudate that is typically associated with swelling.
- blood brain barrier or “BBB” refer the barrier between brain blood vessels and brain tissues whose effect is to restrict what may pass from the blood into the brain.
- cancer refers to a hyperproliferation of cells whose unique trait — loss of normal controls — results in unregulated growth, lack of differentiation, local tissue invasion, and metastasis. Cancer may include a tumor comprised of tumor cells. Those of skill in the art understand that not all cancers comprise tumor cells, for example leukemia does not comprise tumor cells.
- Cerebral ischemia refers to a lack of adequate blood flow to an area, for example a lack of adequate blood flow to the brain, which may be the result of a blood clot, blood vessel constriction, a hemorrhage or tissue compression from an expanding mass.
- depolarization refers to an increase in the permeability of the cell membrane to sodium ions wherein the electrical potential difference across the cell membrane is reduced or eliminated.
- the terms "effective amount” or “therapeutically effective amount” are interchangeable and refer to an amount that results in an improvement or remediation of the symptoms of the disease or condition. Those of skill in the art understand that the effective amount may improve the patient's or subject's condition, but may not be a complete cure of the disease and/or condition.
- endothelium refers a layer of cells that line the inside surfaces of body cavities, blood vessels, and lymph vessels or that form capillaries.
- endothelial cell refers to a cell of the endothelium or a cell that lines the surfaces of body cavities, for example, blood or lymph vessels or capillaries.
- endothelial cell refers to a neural endothelial cell or an endothelial cell that is part of the nervous system, for example the central nervous system or the brain.
- hyperproliferative disease refers to a disease that results from a hyperproliferation of cells.
- hyperproliferative diseases include, but are not limited to cancer, tumors or neoplasms.
- the term "gliotic capsule” refers to a physical barrier surrounding, in whole or in part, a foreign body, including a metastatic tumor, a cerebral abscess or other mass not normally found in brain except under pathological conditions, hi certain embodiments, the gliotic capsule comprises an inner zone comprising neuronal cells, neuroglial cells (e.g., astrocytes) and/or endothelial cells expressing a NCc a -A ⁇ p channel.
- neuroglial cells e.g., astrocytes
- endothelial cells expressing a NCc a -A ⁇ p channel.
- morbidity is the state of being diseased. Yet further, morbidity can also refer to the disease rate or the ratio of sick subjects or cases of disease in to a given population.
- the term "mortality” as used herein is the state of being mortal or causing death. Yet further, mortality can also refer to the death rate or the ratio of number of deaths to a given population.
- neuronal cell refers to a cell that is a morphologic and functional unit of the nervous system.
- the cell comprises a nerve cell body, the dendrites, and the axon.
- the terms neuron, nerve cell, neuronal, neurone, and neurocyte can be used interchangeably.
- Neuronal cell types can include, but are not limited to a typical nerve cell body showing internal structure, a horizontal cell (of Cajal) from cerebral cortex; Martinottic cell, biopolar cell, unipolar cell, Pukinje cell, and a pyramidal cell of motor area of cerebral cortex.
- neural refers to anything associated with the nervous system.
- neuroglia or “neuroglial cell” refers to a cell that is a non-neuronal cellular element of the nervous system.
- the terms neuroglia, neurogliacyte, and neuroglial cell can be used interchangeably.
- Neuroglial cells can include, but are not limited to ependymal cells, astrocytes, oligodendrocytes, or microglia.
- preventing refers to minimizing, reducing or suppressing the risk of developing a disease state or parameters relating to the disease state or progression or other abnormal or deleterious conditions.
- stroke refers to any acute, clinical event related to the impairment of cerebral circulation.
- acute cerebral ischemia and “stroke” can be used interchangeably.
- tumor refers to any swelling tumefaction. Tumor is interchangeable with the term “neoplasm” which is abnormal tissue growth. Tumors can be malignant or benign.
- tumor-brain barrier refers to a biochemical barrier between a foreign body in the brain and the surrounding tissue of the brain.
- the tumor-brain barrier is interchangeably referred to herein as TBB.
- treating refers to administering to a subject a therapeutically effective amount of a composition so that the subject has an improvement in the disease or condition.
- the improvement is any observable or measurable improvement.
- Treating may also comprise treating subjects at risk of developing a disease and/or condition.
- the present invention is directed to therapeutic compositions and methods of using the same.
- the therapeutic composition is an agonist and/or antagonist of a NCc a - ATP channel of a neuronal cell, a neuroglial cell, or a neural endothelial cell.
- the present invention is directed to a method of treating a cancer patient in need of such treatment comprising administering an agonist of a NCc a - A ⁇ p channel of an astrocyte, wherein the agonist activates a NCc a -A TP channel.
- the agonist targets a SURl of the NCc a -A ⁇ p channel.
- the cancer is located in the brain and, more specifically, comprises a metastatic tumor located in the brain.
- the agonist of the present invention disrupts the integrity of the tumor-brain barrier surrounding the cancer, thereby permitting access to otherwise barred agents across the tumor-brain barrier.
- the agonist is administered in combination with an anti-cancer therapy, including chemotherapy, radiotherapy and/or immunotherapy.
- the present invention is directed to a method of disrupting a tumor-brain barrier comprising administering an agonist of a NCc a -A TP channel of an astrocyte, wherein said agonist activates said NCca-Aip channel.
- Methods involving an agonist of the NCc a -ATP channel are directed to selectively killing neuronal cells, neuroglial cells (e.g., astrocytes) and/or neural endothelial cells expressing the NCc a - A TP channel by infusion of an agonist of the NCc a -ATP channel, such as diazoxide, to the astrocyte.
- the infusion can be direct or indirect.
- Selective killing of neuronal cells, neuroglial cells (e.g., astrocytes) and/or neural endothelial cells are desirable when treating a pathology involving a gliotic capsule, such as a metastatic brain tumor.
- the agonist facilitates mounting an immune response, or, alternatively, improves permeability for chemotherapeutic agents.
- the sulfonylurea receptor 1 (SlIRl) is expressed in Rl astrocytes as part of the NCc a -ATP channel, which make up the tumor-brain barrier (TBB) in brain metastasis.
- TBB tumor-brain barrier
- Targeting the SURl of the Rl astrocytes with an agonist thereof compromises the integrity of the TBB, thereby providing a treatment mechanism for metastatic tumors in the brain.
- the agonists of the present invention disrupt the integrity of the gliotic capsule surrounding the foreign body, thereby permitting entry of otherwise barred biological and/or endogenous compounds, such as leukocytes, into the gliotic capsule.
- the agonists include, for example, a compound capable of opening, activating and/or increasing the activity of an neuronal cells, neuroglial cells (e.g., astrocytes) and/or neural endothelial cells expressing NCc a - ATP channel.
- the agonists are SURl activators such as, diazoxide and the like, which are known in the art to open (activate) K channels.
- the present invention is contemplated for use in combination with chemotherapy, immunotherapy and/or radiotherapy.
- solid tumors e.g., tumors in the lung, colon, breast, and brain
- efficient treatment is hindered by the difficulty in penetrating the tumor mass with anti-cancer agents (Jain, 1994).
- the identification of a means by which to facilitate the delivery of therapeutic agents to the cancer site is needed to enhance the effectiveness of current anti-cancer therapies.
- Applicants provide herein methods for enhancing, improving and/or increasing anti-cancer therapies by administering an antagonist of aNCc a - A TP channel.
- various solid tumor models may be used, such as, for example, the well-recognized inducible breast cancer model, from which tumor cells may be harvested and re-implanted into the brain to produce autologous "metastatic" tumors.
- the present invention further describes that the SURl regulatory subunit of this channel is up-regulated in neurons and capillary endothelial cells following ischemia, and blocking this receptor reduces stroke size, cerebral edema and mortality.
- antagonists of the NCc a - A ⁇ p channel may have an important role in preventing, alleviating, inhibiting and/or abrogating the formation of cytotoxic and ionic edema.
- the therapeutic compound of the present invention comprises an antagonist of a NCca-ATP channel of a neuronal cell, a neuroglial cell, a neural endothelial cell or a combination thereof.
- Antagonists are contemplated for use in treating adverse conditions associated with hypoxia and/or ischemia that result in increased intracranial pressure and/or cytotoxic edema of the central nervous system. Such conditions include trauma, ischemic brain injury, namely secondary neuronal injury, and hemorrhagic infarction.
- Antagonists protect the cells expressing the NCc a -A ⁇ p channel, which is desirable for clinical treatment in which gliotic capsule integrity is important and must be maintained to prevent the spread of infection, such as with a brain abscess. The protection via inhibition of the NCc a-A ⁇ p channel is associated with a reduction in cerebral edema.
- the NCc a -ATP channel is blocked, inhibited, or otherwise is decreased in activity.
- an antagonist of the NCc a -ATP channel is administered and/or applied.
- the antagonist modulates the NCc a -ATP channel such that flux through the channel is reduced, ceased, decreased and/or stopped.
- the antagonist may have a reversible or an irreversible activity with respect to the activity of the NCc a-ATP channel of the neuronal cell, neuroglial cell, endothelial cell or a combination thereof.
- the antagonist may prevent or lessen the depolarization of the cells thereby lessening cell swelling due to osmotic changes that can result from depolarization of the cells.
- inhibition of the NCc a - ATP channel can reduce cytotoxic edema and death of endothelial cells.
- Subjects that can be treated with the therapeutic composition of the present invention include, but are not limited subjects suffering from or at risk of developing conditions associated hypoxia and/or ischemia that result in increased intracranial pressure and/or with cytotoxic edema of the central nervous system (CNS).
- Such conditions include, but are not limited to trauma (e.g., traumatic brain injury (TBI), concussion) ischemic brain injury, hemorrhagic infarction, stroke, atrial fibrillations, clotting disorders, pulmonary emboli, arterio ⁇ venous malformations, mass-occupying lesions (e.g., hematomas), etc.
- trauma e.g., traumatic brain injury (TBI), concussion) ischemic brain injury, hemorrhagic infarction, stroke, atrial fibrillations, clotting disorders, pulmonary emboli, arterio ⁇ venous malformations, mass-occupying lesions (e.g., hematomas), etc.
- Still further subjects at risk of developing such conditions can include subjects undergoing treatments that increase the risk of stroke, for example, surgery (vascular or neurological), treatment of myocardial infarction with thrombolytics, cerebral/endovascular treatments, stent placements, angiography, etc.
- Another aspect of the present invention comprises co-administration of an antagonist of the NC CE - ATP channel with a thrombolytic agent. Co-administration of these two compounds increase the therapeutic window of the thrombolytic agent by reducing hemorrhagic conversion.
- the therapeutic window for thrombolytic agents may be increased by several (4-8) hours by co-administering antagonist of the NCc a -ATP channel.
- thrombolytic agent in addition to a thrombolytic agent, other agents can be used in combination with the antagonist of the present invention, for example, but not limited to antiplatelets, anticoagulants, vasodilators, statins, diuretics, etc.
- Another aspect of the present invention comprises the use of labeled SURl antagonists to diagnose, determine or monitor stages of stroke, cerebral edema or visualize the size/boundaries/borders of a tumor and/or the stroke.
- the penumbra following the stroke may be monitored or visualized using labeled SURl antagonists.
- compositions of the present invention can be used to produce neuroprotective kits that are used to treat subjects at risk or suffering from conditions that are associated with cytotoxic cerebral edema.
- the invention is based, in part, on the discovery of a specific channel, the NCc a - A TP channel, defined as a channel on astrocytes in US Application Publication No. 20030215889, which is incorporated herein by reference in its entirety. More specifically, the present invention has further defined that this channel is not only expressed on astrocytes, it is expressed on neural cells, neuroglial cells, and/or neural endothelial cells after brain trauma, for example, an hypoxic event, an ischemic event, or other secondary neuronal injuries relating to these events.
- NCc a - ATP channel is activated by calcium ions (Ca 2+ ) and is sensitive to ATP.
- this channel is a non-selective cation channel activated by intracellular Ca 2+ and blocked by intracellular ATP.
- this channel When opened by depletion of intracellular ATP, this channel is responsible for complete depolarization due to massive Na + influx, which creates an electrical gradient for Cl " and an osmotic gradient for H 2 O, resulting in cytotoxic edema and cell death.
- massive Na + does not occur thereby preventing cytotoxic edema.
- NCc a -ATP channel Certain functional characteristics distinguishes the NCc a -ATP channel from other known ion channels. These characteristics can include, but are not limited to 1) it is a non ⁇ selective cation channels that readily allows passage of Na + , K + and other monovalent cations; 2) it is activated by an increase in intracellular calcium, and/or by a decrease in intracellular ATP; 3) it is regulated by sulfonylurea receptor type 1 (SURl), which heretofore had been considered to be associated exclusively with K ATP channels such as those found in pancreatic ⁇ cells.
- SURl sulfonylurea receptor type 1
- the NCc a -A TP channel of the present invention has a single- channel conductance to potassium ion (K + ) between 20 and 50 pS.
- the NCc a-ATP channel is also stimulated by Ca 2+ on the cytoplasmic side of the cell membrane in a physiological concentration range, where concentration range is from 10 ' to 10 M.
- the NCc a -ATP channel is also inhibited by cytoplasmic ATP in a physiological concentration range, where the concentration range is from 10 '1 to 10 M.
- NCc a - ATP channel is also permeable to the following cations; K + , Cs + , Li + , Na + ; to the extent that the permeability ratio between any two of the cations is greater than 0.5 and less than 2.
- Modulators of the NC Ca -ATP channel are also permeable to the following cations; K + , Cs + , Li + , Na + ; to the extent that the permeability ratio between any two of the cations is greater than 0.5 and less than 2.
- the present invention comprises modulators of the channel, for example agonists and/or antagonist of the channel.
- modulators of the channel for example agonists and/or antagonist of the channel.
- Examples of antagonist or agonist of the present invention may encompass agonist and/or antagonists identified in US Application Publication No. 20030215889, which is incorporated herein by reference in its entirety.
- One of skill in the art is aware that the NCca-ATP channel is comprised to two subunits, the regulatory subunit, SURl, and the pore forming subunit.
- SURl sulfonylurea receptor-1
- suitable SURl antagonists include, but are not limited to glibenclamide, tolbutamide, repaglinide, nateglinide, meglitinide, midaglizole, LY397364, LY389382, glyclazide, glimepiride, estrogen, estrogen related-compounds estrogen related-compounds (estradiol, estrone, estriol, genistein, non-steroidal estrogen (e.g., diethystilbestrol), phytoestrogen (e.g., coumestrol), zearalenone, etc.) and combinations thereof, hi a preferred embodiment of the invention the SURl antagonists is selected from the group consisting of glibenclamide and tolbutamide.
- another antagonist can be MgADP.
- Other antagonist include blockers of KA TP channels, for example, but not limited to tolbutamide, glyburide (l[p-2[5-chloro-O-anisamido)ethyl] phenyl] sulfonyl] -3-cyclohexyl-3-urea); chlopropamide (l-[[(p-chlorophenyl)sulfonyl] -3-propylurea; glipizide (l-cyclohexyl-3[[p-[2(5- methylpyrazine carboxamido) ethyl] phenyl] sulfonyl] urea); or tolazamide(benzenesulfonamide- N-[[(hexahydro-lH-azepin-lyl)amino] carbonyl] -4-methyl).
- Agonists that can be used in the present invention include, but are not limited to agonist of SURl, for example, diazoxide, pinacidil, P 1075, cromakalin or activators of KA TP channels.
- agonists can include, but are not limited to diazoixde derivatives, for example 3- isopropylamino-7-methoxy-4H-l,2,4-benzothiadiazine 1,1 -dioxide (NNC 55-9216), 6,7- dichloro-3-isopropylamino-4H-l,2,4-benzothiadiazine 1,1 -dioxide (BPDZ 154), 7-chloro-3- isopropylamino-4H-l,2,4-benzothiadiazine 1,1-dioxide (BPDZ 73), 6-Chloro-3-isopropylamino- 4 H-thieno[3,2- e]-l,2,4-thiadiazine 1,1-dioxide (NNC 55-0118)4, 6-chloro-3-(l- methylcyclopropyl)amino-4 H-thieno[3,2-e]-l,2,4-thiadiazine 1,1-dioxide (NN414), 3-(
- the modulator can be a compound (protein, nucleic acid, siRNA, etc.) that modulates transcription and/or translation of SURl (regulatory subunit) and/or the molecular entities that comprise the pore-forming subunit.
- SURl regulatory subunit
- Transcription factors are regulatory proteins that binds to a specific DNA sequence ⁇ e.g., promoters and enhancers) and regulate transcription of an encoding DNA region.
- transcription factors can be used to modulate the expression of SURl.
- a transcription factor comprises a binding domain that binds to DNA (a DNA binding domain) and a regulatory domain that controls transcription. Where a regulatory domain activates transcription, that regulatory domain is designated an activation domain. Where that regulatory domain inhibits transcription, that regulatory domain is designated a repression domain. More specifically, transcription factors such as SpI and HIF l ⁇ can be used to modulate expression of SURl.
- An antisense molecule that binds to a translational or transcriptional start site, or splice junctions are ideal inhibitors.
- Antisense, ribozyme, and double-stranded RNA molecules target a particular sequence to achieve a reduction or elimination of a particular polypeptide, such as SURl .
- SURl polypeptide
- Antisense methodology takes advantage of the fact that nucleic acids tend to pair with complementary sequences.
- complementary it is meant that polynucleotides are those which are capable of base-pairing according to the standard Watson-Crick complementarity rules. That is, the larger purines will base pair with the smaller pyrimidines to form combinations of guanine paired with cytosine (G: C) and adenine paired with either thymine (A:T) in the case of DNA, or adenine paired with uracil (A:U) in the case of RNA. Inclusion of less common bases such as inosine, 5-methylcytosine, 6-methyladenine, hypoxanthine and others in hybridizing sequences does not interfere with pairing.
- Targeting double-stranded (ds) DNA with polynucleotides leads to triple-helix formation; targeting RNA will lead to double-helix formation.
- Antisense polynucleotides when introduced into a target cell, specifically bind to their target polynucleotide and interfere with transcription, RNA processing, transport, translation and/or stability.
- Antisense RNA constructs, or DNA encoding such antisense RNAs are employed to inhibit gene transcription or translation or both within a host cell, either in vitro or in vivo, such as within a host animal, including a human subject.
- Antisense constructs are designed to bind to the promoter and other control regions, exons, introns or even exon-intron boundaries of a gene. It is contemplated that the most effective antisense constructs may include regions complementary to intron/exon splice junctions. Thus, antisense constructs with complementarity to regions within 50-200 bases of an intron-exon splice junction are used. It has been observed that some exon sequences can be included in the construct without seriously affecting the target selectivity thereof. The amount of exonic material included will vary depending on the particular exon and intron sequences used. One can readily test whether too much exon DNA is included simply by testing the constructs in vitro to determine whether normal cellular function is affected or whether the expression of related genes having complementary sequences is affected.
- RNA Interference it is advantageous to combine portions of genomic DNA with cDNA or synthetic sequences to generate specific constructs. For example, where an intron is desired in the ultimate construct, a genomic clone will need to be used.
- the cDNA or a synthesized polynucleotide may provide more convenient restriction sites for the remaining portion of the construct and, therefore, would be used for the rest of the sequence.
- RNA interference is used to "knock down” or inhibit a particular gene of interest by simply injecting, bathing or feeding to the organism of interest the double-stranded RNA molecule. This technique selectively “knock downs” gene function without requiring transfection or recombinant techniques (Giet, 2001; Hammond, 2001; Stein P, et al, 2002; Svoboda P, et al, 2001; Svoboda P, et al, 2000).
- siRNA small interfering RNA
- a siRNA may comprises a double stranded structure or a single stranded structure, the sequence of which is "substantially identical" to at least a portion of the target gene (See WO 04/046320, which is incorporated herein by reference in its entirety).
- Identity is the relationship between two or more polynucleotide (or polypeptide) sequences, as determined by comparing the sequences. In the art, identity also means the degree of sequence relatedness between polynucleotide sequences, as determined by the match of the order of nucleotides between such sequences.
- GCG program package (Devereux et al.), BLASTP, BLASTN, and FASTA (Atschul et al.,) and CLUSTAL (Higgins et al, 1992; Thompson, et al, 1994).
- siRNA contains a nucleotide sequence that is essentially identical to at least a portion of the target gene, for example, SURl, or any other molecular entity associated with the NCc a - ATP channel such as the pore-forming subunit.
- SURl nucleic acid sequences for SURl are readily available in GenBank, for example, GenBank accession L40624, which is incorporated herein by reference in its entirety.
- the siRNA contains a nucleotide sequence that is completely identical to at least a portion of the target gene.
- an "identical" RNA sequence when comparing an RNA sequence to a DNA sequence, will contain ribonucleotides where the DNA sequence contains deoxyribonucleotides, and further that the RNA sequence will typically contain a uracil at positions where the DNA sequence contains thymidine.
- dsRNA for use as siRNA and at least 15 contiguous nucleotides of the target gene (e.g., SURl), although a dsRNA having 70%, 75%, 80%, 85%, 90%, or 95% or greater may also be used in the present invention.
- a siRNA that is essentially identical to a least a portion of the target gene may also be a dsRNA wherein one of the two complementary strands (or, in the case of a self-complementary RNA, one of the two self- complementary portions) is either identical to the sequence of that portion or the target gene or contains one or more insertions, deletions or single point mutations relative to the nucleotide sequence of that portion of the target gene.
- siRNA technology thus has the property of being able to tolerate sequence variations that might be expected to result from genetic mutation, strain polymorphism, or evolutionary divergence.
- the first step in designing an siRNA molecule is to choose the siRNA target site, which can be any site in the target gene.
- the target selecting region of the gene which may be an ORF (open reading frame) as the target selecting region and may preferably be 50-100 nucleotides downstream of the "ATG" start codon.
- siRNA Target Designer by Promega
- siRNA Target Finder by GenScript Corp.
- siRNA Retriever Program by Lngenex Corp.
- EMBOSS siRNA algorithm siRNA program by Qiagen
- Ambion siRNA predictor Ambion siRNA predictor
- Whitehead siRNA prediction and Sfold.
- any of the above programs may be utilized to produce siRNA molecules that can be used in the present invention.
- Ribozymes are RNA-protein complexes that cleave nucleic acids in a site- specific fashion. Ribozymes have specific catalytic domains that possess endonuclease activity (Kim and Cech, 1987; Forster and Symons, 1987). For example, a large number of ribozymes accelerate phosphoester transfer reactions with a high degree of specificity, often cleaving only one of several phosphoesters in an oligonucleotide substrate (Cech et al, 1981; Reinhold-Hurek and Shub, 1992). This specificity has been attributed to the requirement that the substrate bind via specific base-pairing interactions to the internal guide sequence ("IGS") of the ribozyme prior to chemical reaction.
- IGS internal guide sequence
- Ribozyme catalysis has primarily been observed as part of sequence specific cleavage/ligation reactions involving nucleic acids (Joyce, 1989; Cech et al, 1981).
- U.S. Patent 5,354,855 reports that certain ribozymes can act as endonucleases with a sequence specificity greater than that of known ribonucleases and approaching that of the DNA restriction enzymes.
- sequence-specific ribozyme-mediated inhibition of gene expression is particularly suited to therapeutic applications (Scanlon et al, 1991; Sarver et al, 1990; Sioud et al, 1992).
- ribozymes include sequences from RNase P with RNA cleavage activity (Yuan et al, 1992; Yuan and Altaian, 1994), hairpin ribozyme structures (Berzal- Herranz et al, 1992; Chowrira et al, 1993) and hepatitis ⁇ virus based ribozymes (Perrotta and Been, 1992).
- the general design and optimization of ribozyme directed RNA cleavage activity has been discussed in detail (Haseloff and Gerlach, 1988; Symons, 1992; Chowrira, et al, 1994; and Thompson, et al, 1995).
- Ribozymes are targeted to a given sequence by virtue of annealing to a site by complimentary base pair interactions. Two stretches of homology are required for this targeting. These stretches of homologous sequences flank the catalytic ribozyme structure defined above. Each stretch of homologous sequence can vary in length from 7 to 15 nucleotides. The only requirement for defining the homologous sequences is that, on the target RNA, they are separated by a specific sequence which is the cleavage site.
- the cleavage site is a dinucleotide sequence on the target RNA, uracil (U) followed by either an adenine, cytosine or uracil (A,C or U; Perriman, et ah, 1992; Thompson, et ah, 1995).
- the frequency of this dinucleotide occurring in any given RNA is statistically 3 out of 16.
- Designing and testing ribozymes for efficient cleavage of a target RNA is a process well known to those skilled in the art. Examples of scientific methods for designing and testing ribozymes are described by Chowrira et al. (1994) and Lieber and Strauss (1995), each incorporated by reference. The identification of operative and preferred sequences for use in SURl targeted ribozymes is simply a matter of preparing and testing a given sequence, and is a routinely practiced screening method known to those of skill in the art.
- Further embodiments of the present invention can include methods for identifying modulators of the NCc a-ATP channel, for example, agonist or antagonist, that modify the activity and/or expression.
- These assays may comprise random screening of large libraries of candidate substances; alternatively, the assays may be used to focus on particular classes of compounds selected with an eye towards structural attributes that are believed to make them more likely to modulate the function or activity or expression of the NCc a - ATP channel.
- the compounds for screening in accordance with the invention include, but are not limited to natural or synthetic organic compounds, peptides, antibodies and fragments thereof, peptidomimetics, that bind to the NCc a -ATP channel and either open the channel ⁇ e.g., agonists) or block the channel ⁇ e.g., antagonists).
- compounds that block the channel are preferred.
- Agonists that open or maintain the channel in the open state include peptides, antibodies or fragments thereof, and other organic compounds that include the SURl subunit of the NCc a - A ⁇ p channel (or a portion thereof) and bind to and "neutralize" circulating ligand for SURl.
- libraries of known compounds can be screened, including natural products or synthetic chemicals, and biologically active materials, including proteins, for compounds which are inhibitors or activators.
- such a compound is an NCc a - ATP antagonist, which includes an NCc a-A TP channel inhibitor, an NCc a -AT P channel blocker, a SURl antagonist, SURl inhibitor, and/or a compound capable of reducing the magnitude of membrane current through the channel.
- Compounds may include, but are not limited to, small organic or inorganic molecules, compounds available in compound libraries, peptides such as, for example, soluble peptides, including but not limited to members of random peptide libraries; (see, e.g., Lam, K. S. et al, 1991, Nature 354: 82-84; Houghten, R. et al, 1991, Nature 354: 84- 86), and combinatorial chemistry-derived molecular library made of D- and/or L- configuration amino acids, phosphopeptides (including, but not limited to, members of random or partially degenerate, directed phosphopeptide libraries; see, e.g., Songyang, Z.
- peptides such as, for example, soluble peptides, including but not limited to members of random peptide libraries; (see, e.g., Lam, K. S. et al, 1991, Nature 354: 82-84; Houghten, R. et al, 1991
- antibodies including, but not limited to, polyclonal, monoclonal, humanized, anti- idiotypic, chimeric or single chain antibodies, and FAb, F(ab') 2 and FAb expression library fragments, and epitope-binding fragments thereof).
- Other compounds which can be screened in accordance with the invention include but are not limited to small organic molecules that are able to cross the blood-brain barrier, gain entry into an appropriate neural cell and affect the expression of the NCc a - A ⁇ p channel gene or some other gene involved in the NCc a - ATP channel activity ⁇ e.g., by interacting with the regulatory region or transcription factors involved in gene expression); or such compounds that affect the activity of the NCc a-ATP channel or the activity of some other intracellular factor involved in the NCc a - A TP channel activity.
- a method may generally comprise: [0152] (a) providing a candidate substance suspected of activating or inhibiting the NCc a -A ⁇ p channel expression or activity in vitro or in vivo;
- an alternative assessing step can be assessing the ability of the candidate substance to bind specifically to the NCc a - ATP channel in vitro or in vivo;
- the NCc a - ATP channel may be provided in a cell or a cell free system and the NCc a - AT P channel may be contacted with the candidate substance.
- the modulator is selected by assessing the effect of the candidate substance on the NCc a - A ⁇ p channel activity or expression.
- the method may further provide manufacturing of the modulator.
- the present invention is directed to a method of treating a cancer patient in need of such treatment comprising administering an agonist of a NCc a - ATP channel of an neuronal cell or a neuroglia cell or a neural endothelial cell, wherein the agonist activates a NCc a-A TP channel, hi specific embodiments, the agonist targets a SURl of the NCc a - ATP channel.
- the cancer is located in the brain and, more specifically, comprises a metastatic tumor located in the brain.
- the present invention is directed to a method of disrupting a tumor-brain barrier comprising administering an agonist of a NCc a-A ⁇ p channel of an astrocyte, wherein said agonist activates said NCca-ATP channel.
- an effective amount of an agonist or antagonist of NCc a - ATP channel that may be administered to a cell includes a dose of about 0.0001 nM to about 2000 ⁇ M.
- doses of an agonist to be administered are from about 0.01 nM to about 2000 ⁇ M; about 0.01 ⁇ M to about 0.05 ⁇ M; about 0.05 ⁇ M to about 1.0 ⁇ M; about 1.0 ⁇ M to about 1.5 ⁇ M; about 1.5 ⁇ M to about 2.0 ⁇ M; about 2.0 ⁇ M to about 3.0 ⁇ M; about 3.0 ⁇ M to about 4.0 ⁇ M; about 4.0 ⁇ M to about 5.0 ⁇ M; about 5.0 ⁇ M to about 10 ⁇ M; about 10 ⁇ M to about 50 ⁇ M; about 50 ⁇ M to about 100 ⁇ M; about 100 ⁇ M to about 200 ⁇ M; about 200 ⁇ M to about 300 ⁇ M; about 300 ⁇ M to about 500 ⁇ M; about 500 ⁇ M to about 1000 ⁇ M; about 1000 ⁇ M to about 1500 ⁇ M and about 1500 ⁇ M to about 2000 ⁇ M.
- all of these amounts are exemplary, and any amount in-between these points is also expected to be of use in
- an agonist of NCc a -A ⁇ p channel or related-compound thereof will inhibit the proliferation of a cell or growth of a neoplasm, either directly or indirectly, by measurably slowing, stopping, or reversing the growth rate of the cell or neoplasm or neoplastic cells in vitro or in vivo. Desirably, the growth rate is slowed by 20%, 30%, 50%, or 70% or more, as determined using a suitable assay for determination of cell growth rates.
- the present invention provides methods for the treatment of a cancer by administering an agonist of the NCc a -ATP channel.
- the agonist or related-compound thereof can be administered parenterally or alimentary.
- Parenteral administrations include, but are not limited to intravenously, intradermally, intramuscularly, intraarterially, intrathecally, intraventricularly, intratumorally, subcutaneous, or intraperitoneally U.S. Pat. Nos. 6,613,308, 5,466,468, 5,543,158; 5,641,515; and 5,399,363 (each specifically incorporated herein by reference in its entirety).
- Alimentary administrations include, but are not limited to orally, buccally, rectally, or sublingually.
- the administration of the therapeutic compounds and/or the therapies of the present invention may include systemic, local and/or regional and may oral, intravenous, and intramuscular.
- routes of administration are also contemplated such as, for example, arterial perfusion, intracavitary, intraperitoneal, intrapleural, intraventricular, intratumoral, intraparenchyma and/or intrathecal.
- the therapeutic compound may be administered by the same route as the chemotherapeutic agent, even if the therapeutic compound and the chemotherapeutic agent are not administered simultaneously.
- the skilled artisan is aware of determining the appropriate administration route using standard methods and procedures. In one example, where assessment of a response to chemotherapy, both peripherally and centrally is desired, the health care professional may use a systemic administration.
- Treatment methods will involve treating an individual with an effective amount of a composition containing an agonist of NCc a - ATP channel or related-compound thereof.
- An effective amount is described, generally, as that amount sufficient to detectably and repeatedly to ameliorate, reduce, minimize or limit the extent of a disease or its symptoms. More specifically, it is envisioned that the treatment with the an agonist of NCc a - ATP channel or related-compounds thereof will kill cells, inhibit cell growth, inhibit cell proliferation, inhibit metastasis, decrease tumor size and otherwise reverse or reduce the malignant phenotype of tumor cells, either directly or indirectly.
- the effective amount of "therapeutically effective amounts" of the an agonist of NCc a - ATP channel or related-compounds thereof to be used are those amounts effective to produce beneficial results, particularly with respect to cancer treatment, in the recipient animal or patient. Such amounts may be initially determined by reviewing the published literature, by conducting in vitro tests or by conducting metabolic studies in healthy experimental animals. Before use in a clinical setting, it may be beneficial to conduct confirmatory studies in an animal model, preferably a widely accepted animal model of the particular disease to be treated. Preferred animal models for use in certain embodiments are rodent models, which are preferred because they are economical to use and, particularly, because the results gained are widely accepted as predictive of clinical value.
- a specific dose level of active compounds such as an agonist of NCc a - ATP channel or related-compounds thereof for any particular patient depends upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination, and the severity of the particular disease undergoing therapy. The person responsible for administration will determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologies standards.
- a therapeutically effective amount of an agonist of NCc a -A ⁇ p channel or related- compounds thereof as a treatment varies depending upon the host treated and the particular mode of administration.
- the dose range of the agonist of NCc a - A ⁇ p channel or related-compounds thereof will be about 0.0001 ⁇ g/kg body weight to about 500 mg/kg body weight.
- body weight is applicable when an animal is being treated. When isolated cells are being treated, “ body weight " as used herein should read to mean “total cell body weight ". The term “total body weight” may be used to apply to both isolated cell and animal treatment.
- a variety of different dosage levels will be of use, for example, 0.0001 ⁇ g/kg, 0.0002 ⁇ g/kg, 0.0003 ⁇ g/kg, 0.0004 ⁇ g/kg, 0.005 ⁇ g/kg, 0.0007 ⁇ g/kg, 0.001 ⁇ g/kg, 0.1 ⁇ g/kg, 1.0 ⁇ g/kg, 1.5 ⁇ g/kg, 2.0 ⁇ g/kg, 5.0 ⁇ g/kg, 10.0 ⁇ g/kg, 15.0 ⁇ g/kg, 30.0 ⁇ g/kg, 50 ⁇ g/kg, 75 ⁇ g/kg, 80 ⁇ g/kg, 90 ⁇ g/kg, 100 ⁇ g/kg, 120 ⁇ g/kg, 140 ⁇ g/kg, 150 ⁇ g/kg, 160 ⁇ g/kg, 180 ⁇ g/kg, 200 ⁇ g/kg, 225 ⁇ g/kg, 250 ⁇ g/kg, 275 ⁇ g/kg, 300 ⁇ g/kg,
- the treatments may include various "unit doses.”
- Unit dose is defined as containing a predetermined quantity of the therapeutic composition (an agonist of NCc a - ATP channel or its related-compounds thereof) calculated to produce the desired responses in association with its administration, e.g., the appropriate route and treatment regimen.
- the quantity to be administered, and the particular route and formulation, are within the skill of those in the clinical arts.
- Also of import is the subject to be treated, in particular, the state of the subject and the protection desired.
- a unit dose need not be administered as a single injection but may comprise continuous infusion over a set period of time.
- the tumor may be infused or perfused with the composition using any suitable delivery vehicle.
- Such continuous perfusion may take place for a period from about 1-2 hours, to about 2-6 hours, to about 6-12 hours, to about 12-24 hours, to about 1-2 days, to about 1-2 wk or longer following the initiation of treatment.
- the dose of the therapeutic composition via continuous perfusion will be equivalent to that given by a single or multiple injections, adjusted over a period of time during which the perfusion occurs.
- the volume to be administered will be about 4-10 ml (preferably 10 ml), while for tumors of ⁇ 4 cm, a volume of about 1-3 ml will be used (preferably 3 ml).
- Multiple injections delivered as single dose comprise about 0.1 to about 1 ml volumes.
- the tumor being treated may not, at least initially, be resectable.
- Treatments with therapeutic agonist of NCc a - ATP channel compositions may increase the resectability of the tumor due to shrinkage at the margins, either directly or indirectly, or by elimination of certain particularly invasive portions. Following treatments, resection may be possible. Additional treatments subsequent to resection will serve to eliminate microscopic residual disease at the tumor site.
- an agonist of NCc a - ATP channel or related-compounds thereof may be used in combination with an additional therapeutic agent to more effectively treat cancer.
- Anticancer agents may include but are not limited to, radiotherapy, chemotherapy, gene therapy, hormonal therapy or immunotherapy that targets cancer/tumor cells.
- the effective amounts of the additional therapeutic agent may simply be defined as that amount effective to inhibit and/or reduce the cancer growth when administered to an animal in combination with an agonist of NCc a -ATP channel or related-compounds thereof. This may be easily determined by monitoring the animal or patient and measuring those physical and biochemical parameters of health and disease that are indicative of the success of a given treatment. Such methods are routine in animal testing and clinical practice.
- This may be achieved by contacting the cell with a single composition or pharmacological formulation that includes both agents, or by contacting the cell with two distinct compositions or formulations, at the same time, wherein one composition includes an agonist of NCc a - ATP channel or derivatives thereof and the other includes the additional agent.
- treatment with an agonist of NCc a - ATP channel or related- compounds thereof may precede or follow the additional agent treatment by intervals ranging from minutes to weeks.
- the additional agent is applied separately to the cell, one would generally ensure that a significant period of time did not expire between the time of each delivery, such that the agent would still be able to exert an advantageously combined effect on the cell. Li such instances, it is contemplated that one would contact the cell with both modalities within about 12-24 hr of each other and, more preferably, within about 6-12 hr of each other, with a delay time of only about 12 hr being most preferred. In some situations, it may be desirable to extend the time period for treatment significantly, however, where several days (2, 3, 4, 5, 6 or 7) to several weeks (1, 2, 3, 4, 5, 6, 7 or 8) lapse between the respective administrations.
- chemotherapy may be administered, as is typical, in regular cycles.
- a cycle may involve one dose, after which several days or the weeks without treatment ensues for normal tissues to recover from the drug's side effects. Doses may be given several days in a row, or every other day for several days, followed by a period of rest. If more than one drug is used, the treatment plan will specify how often and exactly when each drug should be given. The number of cycles a person receives may be determined before treatment starts (based on the type and stage of cancer) or may be flexible, in order to take into account how quickly the tumor is shrinking. Certain serious side effects may also require doctors to adjust chemotherapy plans to allow the patient time to recover.
- Chemotherapeutic agents that may be used in combination with agonists of the present invention or an related-compound thereof in the treatment of cancer, include, but are not limited to cisplatin (CDDP), carboplatin, procarbazine, mechlorethamine, cyclophosphamide, camptothecin, ifosfamide, melphalan, chlorambucil, busulfan, nitrosurea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP 16), tamoxifen, raloxifene, estrogen receptor binding agents, gemcitabien, navelbine, farnesyl-protein tansferase inhibitors, transplatinum, 5-fluorouracil and methotrexate, or any related-compound or derivative variant of the foregoing.
- CDDP cisplatin
- carboplatin procarbazine
- Radiotherapeutic agents may also be use in combination with the compounds of the present invention in treating a cancer.
- factors that cause DNA damage and have been used extensively include what are commonly known as ⁇ -rays, X-rays, and/or the directed delivery of radioisotopes to tumor cells.
- Other forms of DNA damaging factors are also contemplated such as microwaves and UV-irradiation. It is most likely that all of these factors effect a broad range of damage on DNA, on the precursors of DNA, on the replication and repair of DNA, and on the assembly and maintenance of chromosomes.
- Dosage ranges for X-rays range from daily doses of 50 to 200 roentgens for prolonged periods of time (3 to 4 wk), to single doses of 2000 to 6000 roentgens.
- Dosage ranges for radioisotopes vary widely, and depend on the half-life of the isotope, the strength and type of radiation emitted, and the uptake by the neoplastic cells.
- Immunotherapeutics may also be employed in the present invention in combination with an agonist of NCc a -ATP channel or related-compounds thereof in treating cancer.
- Immunotherapeutics generally, rely on the use of immune effector cells and molecules to target and destroy cancer cells.
- the immune effector may be, for example, an antibody specific for some marker on the surface of a tumor cell.
- the antibody alone may serve as an effector of therapy or it may recruit other cells to actually effect cell killing.
- the antibody also may be conjugated to a drug or toxin (chemotherapeutic, radionuclide, ricin A chain, cholera toxin, pertussis toxin, etc.) and serve merely as a targeting agent.
- the effector may be a lymphocyte carrying a surface molecule that interacts, either directly or indirectly, with a tumor cell target.
- Various effector cells include cytotoxic T cells and NK cells.
- the tumor cell must bear some marker that is amenable to targeting, e.g., is not present on the majority of other cells.
- Common tumor markers include carcinoembryonic antigen, prostate specific antigen, urinary tumor associated antigen, fetal antigen, tyrosinase ( ⁇ 97), gp68, TAG-72, HMFG, Sialyl Lewis Antigen, MucA, MucB, PLAP, estrogen receptor, laminin receptor, erb B and pl55. 4.
- Inhibitors of Cellular Proliferation include carcinoembryonic antigen, prostate specific antigen, urinary tumor associated antigen, fetal antigen, tyrosinase ( ⁇ 97), gp68, TAG-72, HMFG, Sialyl Lewis Antigen, MucA, MucB, PLAP, estrogen receptor, laminin receptor, erb B and pl55. 4.
- the tumor suppressor oncogenes function to inhibit excessive cellular proliferation.
- the inactivation of these genes destroys their inhibitory activity, resulting in unregulated proliferation.
- the tumor suppressors p53, pl6 and C-CAM are described below.
- mutant p53 has been found in many cells transformed by chemical carcinogenesis, ultraviolet radiation, and several viruses.
- the p53 gene is a frequent target of mutational inactivation in a wide variety of human tumors and is already documented to be the most frequently mutated gene in common human cancers. It is mutated in over 50% of human NSCLC (Hollstein et al, 1991) and in a wide spectrum of other tumors.
- the p53 gene encodes a 393-amino acid phosphoprotein that can form complexes with host proteins such as large-T antigen and ElB.
- the protein is found in normal tissues and cells, but at concentrations which are minute by comparison with transformed cells or tumor tissue
- Wild-type p53 is recognized as an important growth regulator in many cell types. Missense mutations are common for the p53 gene and are essential for the transforming ability of the oncogene. A single genetic change prompted by point mutations can create carcinogenic p53. Unlike other oncogenes, however, p53 point mutations are known to occur in at least 30 distinct codons, often creating dominant alleles that produce shifts in cell phenotype without a reduction to homozygosity. Additionally, many of these dominant negative alleles appear to be tolerated in the organism and passed on in the germ line. Various mutant alleles appear to range from minimally dysfunctional to strongly penetrant, dominant negative alleles (Winberg, 1991).
- Another inhibitor of cellular proliferation is pi 6.
- the major transitions of the eukaryotic cell cycle are triggered by cyclin-dependent kinases, or CDK' s.
- CDK cyclin-dependent kinase 4
- the activity of this enzyme may be to phosphorylate Rb at late Gl.
- the activity of CDK4 is controlled by an activating subunit, D-type cyclin, and by an inhibitory subunit, the pl6INK4 has been biochemically characterized as a protein that specifically binds to and inhibits CDK4, and thus may regulate Rb phosphorylation (Serrano et al, 1993; Serrano et al, 1995). Since the pl6INK4 protein is a CDK4 inhibitor (Serrano, 1993), deletion of this. gene may increase the activity of CDK4, resulting in hyperphosphorylation of the Rb protein, pi 6 also is known to regulate the function of CDK ⁇ .
- pl6INK4 belongs to a newly described class of CDK-inhibitory proteins that also includes pl6B, pl9, ⁇ 21WAFl, and p27KIPl.
- the pl6INK4 gene maps to 9p21, a chromosome region frequently deleted in many tumor types. Homozygous deletions and mutations of the pl6INK4 gene are frequent in human tumor cell lines. This evidence suggests that the pl6INK4 gene is a tumor suppressor gene.
- genes that may be employed according to the present invention include Rb, mda-7, APC, DCC, NF-I, NF-2, WT-I, MEN-I, MEN-II, zacl, p73, VHL, MMAC1/PTEN, DBCCR-I, FCC, rsk-3, p27, p27/pl6 fusions, p21/p27 fusions, antithrombotic genes (e.g., COX-I, TFPI), PGS, Dp, E2F, ras, myc, neu, raf, erb, fins, trk, ret, gsp, hst, abl, ElA, p300, genes involved in angiogenesis (e.g., VEGF, FGF, thrombospondin, BAI-I, GDAIF, or their receptors) and MCC.
- angiogenesis e.g., VEGF, FGF, thro
- Apoptosis or programmed cell death, is an essential process in cancer therapy (Kerr et al, 1972).
- the Bcl-2 family of proteins and ICE-like proteases have been demonstrated to be important regulators and effectors of apoptosis in other systems.
- the Bcl-2 protein discovered in association with follicular lymphoma, plays a prominent role in controlling apoptosis and enhancing cell survival in response to diverse apoptotic stimuli (Bakhshi et al, 1985; Cleary and Sklar, 1985; Cleary et al, 1986; Tsujimoto et al, 1985; Tsujimoto and Croce, 1986).
- the evolutionarily conserved Bcl-2 protein now is recognized to be a member of a family of related proteins, which can be categorized as death agonists or death antagonists.
- a surgical procedure may be employed in the present invention.
- Approximately 60% of persons with cancer will undergo surgery of some type, which includes preventative, diagnostic or staging, curative and palliative surgery.
- Curative surgery includes resection in which all or part of cancerous tissue is physically removed, excised, and/or destroyed.
- Tumor resection refers to physical removal of at least part of a tumor.
- treatment by surgery includes laser surgery, cryosurgery, electrosurgery, and miscopically controlled surgery (Mohs' surgery).
- the present invention may be used in conjunction with removal of superficial cancers, precancers, or incidental amounts of normal tissue.
- a cavity may be formed in the body.
- Treatment may be accomplished by perfusion, direct injection or local application of the area with an additional anti-cancer therapy.
- Such treatment may be repeated, for example, every 1, 2, 3, 4, 5, 6, or 7 days, or every 1, 2, 3, 4, and 5 weeks or every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months.
- These treatments maybe of varying dosages as well.
- agents may be used in combination with the present invention to improve the therapeutic efficacy of treatment.
- additional agents include immunomodulatory agents, agents that affect the upregulation of cell surface receptors and GAP junctions, cytostatic and differentiation agents, inhibitors of cell adhesion, or agents that increase the sensitivity of the hyperproliferative cells to apoptotic inducers.
- Immunomodulatory agents include tumor necrosis factor; interferon alpha, beta, and gamma; IL-2 and other cytokines; F42K and other cytokine related-compounds; or MIP-I, MTP-lbeta, MCP-I, RANTES, and other chemokines.
- cell surface receptors or their ligands such as Fas / Fas ligand, DR4 or DR5 / TRAIL would potentiate the apoptotic inducing abilities of the present invention by establishment of an autocrine or paracrine effect on hyperproliferative cells. Increased intercellular signaling by elevating the number of GAP junctions would increase the anti-hyperproliferative effects on the neighboring hyperproliferative cell population.
- cytostatic or differentiation agents can be used in combination with the present invention to improve the anti-hyperproliferative efficacy of the treatments.
- Inhibitors of cell adhesion are contemplated to improve the efficacy of the present invention.
- cell adhesion inhibitors are focal adhesion kinase (FAKs) inhibitors and Lovastatin. It is further contemplated that other agents that increase the sensitivity of a hyperproliferative cell to apoptosis, such as the antibody c225, could be used in combination with the present invention to improve the treatment efficacy.
- FAKs focal adhesion kinase
- Lovastatin Lovastatin
- the therapeutic compound of the present invention comprises an antagonist of a NC CA - ATP channel of a neuronal cell, a neuroglial cell, a neural endothelial cell or a combination thereof.
- Antagonists are contemplated for use in treating adverse conditions associated with intracranial pressure and/or cytotoxic edema of the central nervous system. Such conditions include trauma (e.g., traumatic brain injury (TBI)), ischemic brain injury, primary and secondary neuronal injury, stroke, arteriovenous malformations (AVM), mass-occupying lesion (e.g., hematoma), and hemorrhagic infarction.
- TBI traumatic brain injury
- AVM arteriovenous malformations
- mass-occupying lesion e.g., hematoma
- hemorrhagic infarction e.g., hematoma
- Antagonists protect the cells expressing the NC CA -A TP channel, which is desirable for clinical treatment in which ionic or cytotoxic edema is formed, in which capillary integrity is lost following ischemia, and in which gliotic capsule integrity is important and must be maintained to prevent the spread of infection, such as with a brain abscess.
- a brain abscess is a completely enclosed and results in cerebral swelling.
- the protection via inhibition of the NC CA - AT P channel is associated with a reduction in cerebral ionic and cytotoxic edema.
- the compound that inhibits the NC CA - ATP channel is neuroprotective.
- the NC CA - ATP channel is blocked, inhibited, or otherwise is decreased in activity
- an antagonist of the NC CA -A TP channel is administered and/or applied.
- the antagonist modulates the NC CA - ATP channel such that flux (ion and/or water) through the channel is reduced, ceased, decreased and/or stopped.
- the antagonist may have a reversible or an irreversible activity with respect to the activity of the NC C A-A TP channel of the neuronal cell, neuroglial cell, a neural endothelial cell or a combination thereof.
- inhibition of the NC CA -A TP channel can reduce cytotoxic edema and death of endothelial cells which are associated with formation of ionic edema and with hemorrhagic conversion.
- the present invention is useful in the treatment or alleviation of acute cerebral ischemia.
- the administration of effective amounts of the active compound can block the channel, which if remained open leads to neuronal cell swelling and cell death.
- a variety of antagonists to SURl are suitable for blocking the channel. Examples of suitable SURl antagonists include, but are not limited to glibenclamide, tolbutamide, repaglinide, nateglinide, meglitinide, midaglizole, LY397364, LY389382, glyclazide, glimepiride, estrogen, estrogen related-compounds and combinations thereof.
- the SURl antagonists is selected from the group consisting of glibenclamide and tolbutamide.
- Another antagonist that can be used is MgADP.
- Still other therapeutic "strategies" for preventing neural cell swelling and cell death can be adopted including, but not limited to methods that maintain the neural cell in a polarized state and methods that prevent strong depolarization.
- inhibitors or antagonist of the NC C A-A TP channel can be used to reduce or alleviate or abrogate hemorrhagic conversion.
- the pathological sequence that takes place in capillaries after ischemia can be divided into 3 stages, based on the principal constituents that move from the intravascular compartment into brain parenchyma (Ayata 2002; Betz, 1996; Betz 1989).
- the first stage is characterized by formation of "ionic" edema, during which the BBB remains intact, with movement of electrolytes (Na + , Cl " ) plus water into brain parenchyma.
- the second stage is characterized by formation of "vasogenic" edema, due to breakdown of the BBB, during which macromolecules plus water enter into brain parenchyma.
- the third stage is characterized by hemorrhagic conversion, due to catastrophic failure of capillaries, during which all constituents of blood extravasate into brain parenchyma.
- understanding these phases requires that 2 things be identified: (i) the driving force that "pushes" things into parenchyma; and (ii) the permeability pore that allows passage of these things into parenchyma.
- the use of the antagonist or related-compounds thereof can reduce the mortality of a subject suffering from a stroke and/or rescue the penumbra area or prevent damage in the penumbra area which comprises areas of tissue that are at risk of becoming irreversibly damaged.
- Neuronal cells in which the antagonist of the NCc a - ATP channel may be administered may include any cell that expresses SURl, for example any neuronal cell, neuroglial cell or a neural endothelia cell.
- Subjects that may be treated with the antagonist or related-compound thereof include those that are suffering from or at risk of developing trauma (e.g., traumatic brain injury (TBI)), ischemic brain injury, primary and secondary neuronal injury, stroke, arteriovenous malformations (AVM), brain abscess, mass-occupying lesion, hemorrhagic infarction, or any other condition associated with cerebral hypoxia or cerebral ischemia resulting in cerebral edema and/or increased intracranial pressure, for example, but not limited to brain mass, brain edema, hematoma, end stage cerebral edema, encephalopathies, etc.
- the antagonist can be a therapeutic treatment in which the therapeutic treatment includes prophylaxis or a prophylactic treatment.
- the antagonist or related-compounds thereof are neuroprotective.
- Other subjects that may be treated with the antagonist of the present invention include those subjects that are at risk or predisposed to developing a stroke. Such subjects can include, but are not limited to subjects that suffer from atrial fibrillations, clotting disorders, and/or risk of pulmonary emboli.
- a subject at risk for developing a stroke may include subjects undergoing treatments, for example, but not limited to cerebral/endo vascular treatments, surgery (e.g., craniotomy, cranial surgery, removal of brain tumors (e.g., hematoma), coronary artery bypass grafting (CABG), angiography, stent replacement, other vascular surgeries, and/or other CNS or neurological surgeries), and treatment of myocardial infarction (MI) with thrombolytics.
- the subject may be treated with the antagonist or related-compound of the present invention prior to the actual treatment.
- Pretreatment can include administration of the antagonist and/or related-compound months (1, 2, 3, etc.), weeks (1, 2, 3, etc.), days (1, 2, 3, etc.), hours (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12), or minutes (15, 30, 60, 90, etc.) prior to the actual treatment or surgery.
- Treatment of the antagonist and/or related-compound can continue during the treatment and/or surgery and after the treatment and/or surgery until the risk of developing a stroke in the subject is decreased, lessened or alleviated.
- the antagonist of the present invention can be given to a subject at risk of developing head/neck trauma, such as a subject involved in sports or other activities that have an increased risk of head/neck trauma.
- An effective amount of an antagonist of the NCc a - A ⁇ p channel that may be administered to a cell includes a dose of about 0.0001 iiM to about 200OuM. More specifically, doses of an agonist to be administered are from about 0.01 nM to about 2000 ⁇ M; about 0.01 ⁇ M to about 0.05 ⁇ M; about 0.05 ⁇ M to about 1.0 ⁇ M; about 1.0 ⁇ M to about 1.5 ⁇ M; about 1.5 ⁇ M to about 2.0 ⁇ M; about 2.0 ⁇ M to about 3.0 ⁇ M; about 3.0 ⁇ M to about 4.0 ⁇ M; about 4.0 ⁇ M to about 5.0 ⁇ M; about 5.0 ⁇ M to about 10 ⁇ M; about 10 ⁇ M to about 50 ⁇ M; about 50 ⁇ M to about 100 ⁇ M; about 100 ⁇ M to about 200 ⁇ M; about 200 ⁇ M to about 300 ⁇ M; about 300 ⁇ M to about 500 ⁇ M; about 500 ⁇ M to about 1000 ⁇ M;
- the antagonist or related-compound thereof can be administered parenterally or alimentary.
- Parenteral administrations include, but are not limited to intravenously, intradermally, intramuscularly, intraarterially, intrathecally, subcutaneous, or intraperitoneally U.S. Pat. Nos. 6,613,308, 5,466,468, 5,543,158; 5,641,515; and 5,399,363 (each specifically incorporated herein by reference in its entirety).
- Alimentary administrations include, but are not limited to orally, buccally, rectally, or sublingually.
- the administration of the therapeutic compounds and/or the therapies of the present invention may include systemic, local and/or regional administrations, for example, topically (dermally, transdermally), via catheters, implantable pumps, etc.
- routes of administration are also contemplated such as, for example, arterial perfusion, intracavitary, intraperitoneal, intrapleural, intraventricular and/or intrathecal.
- the skilled artisan is aware of determining the appropriate administration route using standard methods and procedures. Other routes of administration are discussed elsewhere in the specification and are incorporated herein by reference.
- Treatment methods will involve treating an individual with an effective amount of a composition containing an antagonist of NCc a -ATP channel or related-compound thereof.
- An effective amount is described, generally, as that amount sufficient to detectably and repeatedly to ameliorate, reduce, minimize or limit the extent of a disease or its symptoms. More specifically, it is envisioned that the treatment with the an antagonist of NCc a - AT P channel or related- compounds thereof will inhibit cell depolarization, inhibit Na + influx, inhibit an osmotic gradient change, inhibit water influx into the cell, inhibit cytotoxic cell edema, decrease stroke size, inhibit hemorrhagic conversion, and decrease mortality of the subject.
- the effective amount of an antagonist of NC Ca - AT P channel or related- compounds thereof to be used are those amounts effective to produce beneficial results, particularly with respect to stroke treatment, in the recipient animal or patient. Such amounts may be initially determined by reviewing the published literature, by conducting in vitro tests or by conducting metabolic studies in healthy experimental animals. Before use in a clinical setting, it may be beneficial to conduct confirmatory studies in an animal model, preferably a widely accepted animal model of the particular disease to be treated. Preferred animal models for use in certain embodiments are rodent models, which are preferred because they are economical to use and, particularly, because the results gained are widely accepted as predictive of clinical value.
- a specific dose level of active compounds such as an antagonist of the NCc a - ATP channel or related-compounds thereof for any particular patient depends upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination, and the severity of the particular disease undergoing therapy. The person responsible for administration will determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologies standards.
- the effective amount of the antagonist or related-compound thereof can be the amount that is required to achieve the desired result: reduction in the risk of stroke, reduction in intracranial pressure, reduction in cell death, reduction in stroke size, etc.
- This amount also is an amount that maintains a reasonable level of blood glucose in the patient, for example, the amount of the antagonist maintains a blood glucose level of at least 60 mniol/1, more preferably, the blood glucose level is maintain in the range of about 60 mmol/1 to about 150 mmol/1.
- the amounts prevents the subject from becoming hypoglycemic. If glucose levels are not normal, then one of skill in the art would administer either insulin or glucose, depending upon if the patient is hypoglycemic or hyperglycemic.
- an effective amount of an antagonist of the NCc a - ATP channel or related- compounds thereof as a treatment varies depending upon the host treated and the particular mode of administration.
- the dose range of the antagonist of the NCc a - A TP channel or related-compounds thereof will be about 0.01 ⁇ g/kg body weight to about 20,000 ⁇ g/kg body weight.
- body weight is applicable when an animal is being treated. When isolated cells are being treated, “ body weight " as used herein should read to mean “total cell body weight ". The term “total body weight” may be used to apply to both isolated cell and animal treatment.
- a variety of different dosage levels will be of use, for example, 0.0001 ⁇ g/kg, 0.0002 ⁇ g/kg, 0.0003 ⁇ g/kg, 0.0004 ⁇ g/kg, 0.005 ⁇ g/kg, 0.0007 ⁇ g/kg, 0.001 ⁇ g/kg, 0.1 ⁇ g/kg, 1.0 ⁇ g/kg, 1.5 ⁇ g/kg, 2.0 ⁇ g/kg, 5.0 ⁇ g/kg, 10.0 ⁇ g/kg, 15.0 ⁇ g/kg, 30.0 ⁇ g/kg, 50 ⁇ g/kg, 75 ⁇ g/kg, 80 ⁇ g/kg, 90 ⁇ g/kg, 100 ⁇ g/kg, 120 ⁇ g/kg, 140 ⁇ g/kg, 150 ⁇ g/kg, 160 ⁇ g/kg, 180 ⁇ g/kg, 200 ⁇ g/kg, 225 ⁇ g/kg, 250 ⁇ g/kg, 275 ⁇ g/kg, 300 ⁇ g/kg,
- the treatments may include various "unit doses.”
- Unit dose is defined as containing a predetermined quantity of the therapeutic composition (an antagonist of the NCc a - ATP channel or its related-compounds thereof) calculated to produce the desired responses in association with its administration, e.g., the appropriate route and treatment regimen.
- the quantity to be administered, and the particular route and formulation, are within the skill of those in the clinical arts.
- Also of import is the subject to be treated, in particular, the state of the subject and the protection desired.
- a unit dose need not be administered as a single injection but may comprise continuous infusion over a set period of time.
- an antagonist of the NCc a -ATP channel or related-compounds thereof may be used in combination with an additional therapeutic agent to more effectively treat a cerebral ischemic event, and/or decrease intracranial pressure.
- a conventional therapy or agent including but not limited to, a pharmacological therapeutic agent may be combined with the antagonist or related-compound of the present invention.
- Non-limiting examples of a pharmacological therapeutic agent that may be used in the present invention include an antihyperlipoproteinemic agent, an antiarteriosclerotic agent, an anticholesterol agent, an antiinflammatory agent, an antithrombotic/fibrinolytic agent, anticoagulant, antiplatelet, vasodilator, and/or diuretics.
- Thromoblytics that are used can include, but are not limited to prourokinase, streptokinase, and tissue plasminogen activator (tPA)
- Anticholesterol agents include but are not limited to HMG-CoA Reductase inhibitors, cholesterol absorption inhibitors, bile acid sequestrants, nicotinic acid and derivatives thereof, fibric acid and derivatives thereof.
- HMG-CoA Reductase inhibitors include statins, for example, but not limited to atorvastatin calcium (Lipitor®), cerivastatin sodium (Baycol®), fluvastatin sodium (Lescol®), lovastatin (Advicor®), pravastatin sodium (Pravachol®), and simvastatin (Zocor®).
- Agents known to reduce the absorption of ingested cholesterol include, for example, Zetia®.
- Bile acid sequestrants include, but are not limited to cholestyramine, cholestipol and colesevalam.
- anticholesterol agents include fibric acids and derivatives thereof (e.g., gemfibrozil, fenofibrate and clofibrate); nicotinic acids and derivatives thereof (e.g., antibiotic an, lovastatin) and agents that extend the release of nicotinic acid, for example niaspan.
- Antiinflammatory agents include, but are not limited to non-sterodial anti-inflammatory agents (e.g., naproxen, ibuprofen, celeoxib) and sterodial anti-inflammatory agents (e.g., glucocorticoids).
- Anticoagulants include, but are not limited to heparin, warfarin, and Coumadin.
- Antiplatelets include, but are not limited to aspirin, and aspirin related-compounds, for example acetaminophen.
- Diuretics include, but are not limited to such as furosemide (Lasix®), bumetanide (Bumex®), torsemide (Demadex®), thiazide & thiazide-like diuretics (e.g., chlorothiazide (Diuril®) and hydrochlorothiazide (Esidrix®), benzthiazide, cyclothiazide, indapamide, chlorthalidone, bendrofluniethizide, metolazone), amiloride, triamterene, and spironolacton.
- Vasodilators include, but are not limited to nitroglycerin,
- the present invention comprises co ⁇ administration of an antagonist of the NCc a -A ⁇ p channel with a thrombolytic agent.
- Co ⁇ administration of these two compounds will increase the therapeutic window of the thrombolytic agent.
- suitable thrombolytic agents that can be employed in the methods and pharmaceutical compositions of this invention are prourokinase, streptokinase, and tissue plasminogen activator (tPA).
- the present invention comprises co-administration of an antagonist of the NCc a - A ⁇ p channel with glucose or related carbohydrate to maintain appropriate levels of serum glucose.
- Appropriate levels of blood glucose are within the range of about 60 mmol/1 to about 150 mmol/liter.
- glucose or a related carbohydrate is administered in combination to maintain the serum glucose within this range.
- the effective amounts of the additional therapeutic agent may simply be defined as that amount effective to reduce cerebral edema when administered to an animal in combination with an agonist of NCc a - ATP channel or related-compounds thereof. This may be easily determined by monitoring the animal or patient and measuring those physical and biochemical parameters of health and disease that are indicative of the success of a given treatment. Such methods are routine in animal testing and clinical practice.
- compositions of the present invention To inhibit hemorrhagic conversion, reduce cell swelling, etc., using the methods and compositions of the present invention, one would generally contact a cell with antagonist of NCc a - ATP channel or related-compounds thereof in combination with an additional therapeutic agent, such as tPA, aspirin, statins, diuretics, warfarin, Coumadin, mannitol, etc. These compositions would be provided in a combined amount effective to inhibit hemorrhagic conversion, cell swelling and edema. This process may involve contacting the cells with agonist of NCc a - ATP channel or related-compounds thereof in combination with an additional therapeutic agent or factor(s) at the same time.
- additional therapeutic agent such as tPA, aspirin, statins, diuretics, warfarin, Coumadin, mannitol, etc.
- This may be achieved by contacting the cell with a single composition or pharmacological formulation that includes both agents, or by contacting the cell with two distinct compositions or formulations, at the same time, wherein one composition includes an antagonist of the NCc a - ATP channel or derivatives thereof and the other includes the additional agent.
- treatment with an antagonist of NCc a -A ⁇ p channel or related- compounds thereof may precede or follow the additional agent treatment by intervals ranging from minutes to hours to weeks to months.
- additional agent is applied separately to the cell, one would generally ensure that a significant period of time did not expire between the time of each delivery, such that the agent would still be able to exert an advantageously combined effect on the cell.
- thrombolytic agent typically, for maximum benefit of the thrombolytic agent, or therapy must be started within three hours of the onset of stroke symptoms, making rapid diagnosis and differentiation of stroke and stroke type critical.
- administration of the NCc a -ATP channel with a thrombolytic agent increases this therapeutic window.
- the therapeutic window for thrombolytic agents may be increased by several (4-8) hours by co-administering antagonist of the NCc a -ATP channel.
- the combination of the antagonist and tPA results in a decrease or prevention of hemorrhagic conversion following reperfusion.
- Hemorrhagic conversion is the transformation of a bland infarct into a hemorrhagic infarct after restoration of circulation. It is generally accepted that these complications of stroke and of reperfusion are attributable to capillary endothelial cell dysfunction that worsens as ischemia progresses.
- the present invention is protective of the endothelial cell dysfunction that occurs as a result of an ischemic event.
- Endothelial cell dysfunction comprises three phases. Phase one is characterized by formation of ionic edema with the blood brain barrier still intact. The second phase is characterized by formation of vasogenic edema in which the blood brain barrier is no longer intact. Phase three is characterized by hemorrhagic conversion due to failure of capillary integrity during which all constituents of blood, including erythrocytes, extravasate into brain parenchyma. Disruption of BBB involves ischemia-induced activation of endothelial cells that results in expression and release of MMPs, specifically, MMP-2 (gelatinase A) and MMP-9 (gelatinase B).
- hemorrhagic conversion increases mortality of the patient, it is essential that these patients receive treatment in an urgent manner. For example, it is known that hemorrhagic conversion typically results in patients if reperfusion and tPA treatment is delayed beyond 3 hr or more after thrombotic stroke. Thus, the administration of the antagonist of the present invention will reduce necrotic death of ischemic endothelial cells, and will thereby prolong the therapeutic window for tPA, thereby decreasing mortality of the patient. VII. Diagnostics
- the antagonist or related-compound can be used for diagnosing, monitoring, or prognosis of ischemia or damage to neurons, glial cells or in monitoring neuronal cells in zones of cerebral edema, metastatic tumors, etc.
- One embodiment of the instant invention comprises a method for detecting expression of any portion of a Nac a - A ⁇ p channel, for example, expression of the regulatory unit, SURl, and/or expression of the pore-forming subunit. This may comprise determining the level of SURl expressed and/or the level of the pore-forming subunit expressed. It is understood by the present invention that the up-regulation or increased expression of the Nac a-A ⁇ p channel relates to increased levels of SURl, which correlates to increased neuronal damage, such as cerebral edema.
- a biological sample is obtained from a subject.
- the biological sample may be tissue or fluid.
- the biological sample includes cells from the brain and/or cerebral endothelial cells or microvessels and/or gliotic capsule. For example, in metastatic tumors, glial cells are activated and form a capsule around the tumor.
- Nucleic acids used are isolated from cells contained in the biological sample, according to standard methodologies (Sambrook et at, 1989).
- the nucleic acid may be genomic DNA or fractionated or whole cell RNA. Where RNA is used, it may be desired to convert the RNA to a complementary DNA (cDNA).
- cDNA complementary DNA
- the RNA is whole cell RNA; in another, it is poly-A RNA. Normally, the nucleic acid is amplified.
- the specific nucleic acid of interest is identified in the sample directly using amplification or with a second, known nucleic acid following amplification.
- the identified product is detected.
- the detection may be performed by visual means ⁇ e.g., ethidium bromide staining of a gel).
- the detection may involve indirect identification of the product via chemiluminescence, radioactive scintigraphy of radiolabel or fluorescent label or even via a system using electrical or thermal impulse signals (Affymax Technology; Bellus, 1994).
- Affymax Technology Affymax Technology; Bellus, 1994.
- chip-based DNA technologies such as those described by Hacia et al, (1996) and Shoemaker et al, (1996) can be used for diagnosis. Briefly, these techniques involve quantitative methods for analyzing large numbers of genes rapidly and accurately. By tagging genes with oligonucleotides or using fixed probe arrays, one can employ chip technology to segregate target molecules as high density arrays and screen these molecules on the basis of hybridization. See also Pease et al, (1994); Fodor et al, (1991).
- conjugates are those conjugates in which the molecule (for example, protein, antibody, and/or compound) is linked to a detectable label.
- Detectable labels are compounds and/or elements that can be detected due to their specific functional properties, and/or chemical characteristics, the use of which allows the antibody to which they are attached to be detected, and/or further quantified if desired.
- Conjugates are generally preferred for use as diagnostic agents. Diagnostics generally fall within two classes, those for use in in vitro diagnostics, such as in a variety of immunoassays, and/or those for use in vivo diagnostic protocols, generally known as "molecule-directed imaging".
- imaging agents are known in the art, as are methods for their attachment to molecules, for example, antibodies (see, for e.g., U.S. Patent Nos. 5,021,236; 4,938,948; and 4,472,509, each incorporated herein by reference).
- the imaging moieties used can be paramagnetic ions; radioactive isotopes; fluorochromes; NMR-detectable substances; X- ray imaging.
- ions such as chromium (III), manganese (II), iron (III), iron (II), cobalt (II), nickel (II), copper (II), neodymium (III), samarium (III), ytterbium (III), gadolinium (III), vanadium (II), terbium (III), dysprosium (III), holmium (IH) and/or erbium (HI), with gadolinium being particularly preferred.
- Ions useful in other contexts, such as X-ray imaging include but are not limited to lanthanum (III), gold (III), lead (II), and especially bismuth (III).
- radioactive isotopes for therapeutic and/or diagnostic application, one might mention astatine 211 , ⁇ carbon, 14 carbon, 51 chromium, 36 chlorine, 57 cobalt, 58 cobalt, copper 67 , 152 Eu, gallium 67 , 3 hydrogen, iodine 123 , iodine 125 , iodine 131 , indium 111 , 59 iron, 32 phosphorus, rhenium 186 , rhenium 188 , 75 selenium, 35 sulphur, technicium 99 " 1 and/or yttrium 90 .
- 125 I is often being preferred for use in certain embodiments, and technicium 99 " 1 and/or indium 111 are also often preferred due to their low energy and suitability for long range detection.
- fluorescent labels contemplated for use as conjugates include Alexa 350, Alexa 430, AMCA, BODIPY 630/650, BODIPY 650/665, BODIPY-FL, BODIPY-R6G, BODIPY-TMR, BODIPY-TRX, Cascade Blue, Cy3, Cy5,6-FAM, Fluorescein Isothiocyanate, HEX, 6- JOE, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, REG, Rhodamine Green, Rhodamine Red, Renographin, ROX, TAMRA, TET, Tetramethylrhodamine, and/or Texas Red.
- conjugates contemplated in the present invention are those intended primarily for use in vitro, where the molecule is linked to a secondary binding ligand and/or to an enzyme (an enzyme tag) that will generate a colored product upon contact with a chromogenic substrate.
- suitable enzymes include urease, alkaline phosphatase, (horseradish) hydrogen peroxidase or glucose oxidase.
- Preferred secondary binding ligands are biotin and/or avidin and streptavidin compounds. The use of such labels is well known to those of skill in the art and are described, for example, in U.S. Patents 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149 and 4,366,241; each incorporated herein by reference.
- Immunoassays in their most simple and direct sense, are binding assays. Certain preferred immunoassays are the various types of radioimmunoassays (RIA) and immunobead capture assay. Immunohistochemical detection using tissue sections also is particularly useful. However, it will be readily appreciated that detection is not limited to such techniques, and Western blotting, dot blotting, FACS analyses, and the like also may be used in connection with the present invention.
- Irnrnunologically-based detection methods for use in conjunction with Western blotting include enzymatically-, radiolabel-, or fluorescently-tagged secondary molecules/antibodies against the SURl or regulatory subunit of the Nac aATP channel are considered to be of particular use in this regard.
- U.S. Patents concerning the use of such labels include 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149 and 4,366,241, each incorporated herein by reference.
- a secondary binding ligand such as a second antibody or a biotin/avidin ligand binding arrangement, as is known in the art.
- PET scans involves the acquisition of physiologic images based on the detection of radiation from the emission of positrons.
- Positrons are tiny particles emitted from a radioactive substance administered to the subject.
- the antagonist or related- compound thereof is enzymatically-, radiolabel-, or fluorescently-tagged, as described above and used to diagnosis, monitor, and/or stage neuronal damage by cerebral edema.
- the enzymatically-, radiolabel-, or fluorescently-tagged antagonist or related-compound thereof can be used to determine the size, limits and/or boundaries of tumors. It is difficult to determine the boundaries of certain tumors, for example, metastatic tumors. In metastatic tumors, glial cells are activated and form a capsule or gliotic capsule around the tumor.
- the labeled antagonist or related-compound thereof can be used to determine the border of tumor, which can enhance the efficiency of its removal by the surgeon. Still further, the labeled antagonist or related-compound thereof may be used to determine or define the penumbra or the areas at risk for later infarction or damage after a stroke.
- compositions of the present invention comprise an effective amount of one or more modulators of NCc a -ATP channel (antagonist and/or agonist) or related- compounds or additional agent dissolved or dispersed in a pharmaceutically acceptable carrier.
- modulators of NCc a -ATP channel antagonist and/or agonist
- related- compounds or additional agent dissolved or dispersed in a pharmaceutically acceptable carrier.
- pharmaceutically acceptable refers to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, such as, for example, a human, as appropriate.
- pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329, incorporated herein by reference). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the pharmaceutical compositions is contemplated.
- the modulators of NCcaATP channel (antagonist and/or agonist) or related- compounds may comprise different types of carriers depending on whether it is to be administered in solid, liquid or aerosol form, and whether it need to be sterile for such routes of administration as injection.
- the present invention can be administered intravenously, intradermally, transdermally, intrathecally, intraventricularly, intraarterially, intraperitoneally, intranasally, intravaginally, intrarectally, topically, intramuscularly, subcutaneously, mucosally, orally, topically, locally, inhalation (e.g., aerosol inhalation), injection, infusion, continuous infusion, localized perfusion bathing target cells directly, via a catheter, via a lavage, in cremes, in lipid compositions (e.g., liposomes), or by other method or any combination of the forgoing as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed.
- the modulators of NCc a -A ⁇ p channel (antagonist and/or agonist) or related- compounds may be formulated into a composition in a free base, neutral or salt form.
- Pharmaceutically acceptable salts include the acid addition salts, e.g., those formed with the free amino groups of a proteinaceous composition, or which are formed with inorganic acids such as for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric or mandelic acid.
- Salts formed with the free carboxyl groups can also be derived from inorganic bases such as for example, sodium, potassium, ammonium, calcium or ferric hydroxides; or such organic bases as isopropylamine, trimethylamine, histidine or procaine.
- solutions Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.
- the formulations are easily administered in a variety of dosage forms such as formulated for parenteral administrations such as injectable solutions, or aerosols for delivery to the lungs, or formulated for alimentary administrations such as drug release capsules and the like.
- the composition of the present invention suitable for administration is provided in a pharmaceutically acceptable carrier with or without an inert diluent.
- the carrier should be assimilable and includes liquid, semi-solid, i.e., pastes, or solid carriers. Except insofar as any conventional media, agent, diluent or carrier is detrimental to the recipient or to the therapeutic effectiveness of a the composition contained therein, its use in administrable composition for use in practicing the methods of the present invention is appropriate.
- carriers or diluents include fats, oils, water, saline solutions, lipids, liposomes, resins, binders, fillers and the like, or combinations thereof.
- composition may also comprise various antioxidants to retard oxidation of one or more component. Additionally, the prevention of the action of microorganisms can be brought about by preservatives such as various antibacterial and antifungal agents, including but not limited to parabens (e.g., methylparabens, propylparabens), chlorobutanol, phenol, sorbic acid, thimerosal or combinations thereof.
- parabens e.g., methylparabens, propylparabens
- chlorobutanol phenol
- sorbic acid thimerosal or combinations thereof.
- the composition is combined with the carrier in any convenient and practical manner, i.e., by solution, suspension, emulsification, admixture, encapsulation, absorption and the like. Such procedures are routine for those skilled in the art.
- the composition is combined or mixed thoroughly with a semi-solid or solid carrier.
- the mixing can be carried out in any convenient manner such as grinding.
- Stabilizing agents can be also added in the mixing process in order to protect the composition from loss of therapeutic activity, i.e., denaturation in the stomach.
- stabilizers for use in an the composition include buffers, amino acids such as glycine and lysine, carbohydrates such as dextrose, mannose, galactose, fructose, lactose, sucrose, maltose, sorbitol, mannitol, etc.
- the present invention may concern the use of a pharmaceutical lipid vehicle compositions that include modulators of NCc aATP channel (antagonist and/or agonist) or related-compounds, one or more lipids, and an aqueous solvent.
- lipid will be defined to include any of a broad range of substances that is characteristically insoluble in water and extractable with an organic solvent. This broad class of compounds are well known to those of skill in the art, and as the term "lipid” is used herein, it is not limited to any particular structure. Examples include compounds which contain long-chain aliphatic hydrocarbons and their derivatives. A lipid may be naturally occurring or synthetic (i.e., designed or produced by man).
- a lipid is usually a biological substance.
- Biological lipids are well known in the art, and include for example, neutral fats, phospholipids, phosphoglycerides, steroids, terpenes, lysolipids, glycosphingolipids, glycolipids, sulphatides, lipids with ether and ester-linked fatty acids and polymerizable lipids, and combinations thereof.
- neutral fats phospholipids, phosphoglycerides, steroids, terpenes, lysolipids, glycosphingolipids, glycolipids, sulphatides, lipids with ether and ester-linked fatty acids and polymerizable lipids, and combinations thereof.
- compounds other than those specifically described herein that are understood by one of skill in the art as lipids are also encompassed by the compositions and methods of the present invention.
- the modulators of NCc aATP channel (antagonist and/or agonist) or related-compounds may be dispersed in a solution containing a lipid, dissolved with a lipid, emulsified with a lipid, mixed with a lipid, combined with a lipid, covalently bonded to a lipid, contained as a suspension in a lipid, contained or complexed with a micelle or liposome, or otherwise associated with a lipid or lipid structure by any means known to those of ordinary skill in the art.
- the dispersion may or may not result in the formation of liposomes.
- the actual dosage amount of a composition of the present invention administered to an animal patient can be determined by physical and physiological factors such as body weight, severity of condition, the type of disease being treated, previous or concurrent therapeutic and/or prophylatic interventions, idiopathy of the patient and on the route of administration. Depending upon the dosage and the route of administration, the number of administrations of a preferred dosage and/or an effective amount may vary according tot he response of the subject. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject.
- compositions may comprise, for example, at least about 0.1% of an active compound.
- the an active compound may comprise between about 2% to about 75% of the weight of the unit, or between about 25% to about 60%, for example, and any range derivable therein.
- the amount of active compound(s) in each therapeutically useful composition may be prepared is such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.
- the modulators of NCc aATP channel (antagonist and/or agonist) or related-compounds are formulated to be administered via an alimentary route.
- Alimentary routes include all possible routes of administration in which the composition is in direct contact with the alimentary tract.
- the pharmaceutical compositions disclosed herein may be administered orally, buccally, rectally, or sublingually.
- these compositions may be formulated with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard- or soft- shell gelatin capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.
- the active compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tables, troches, capsules, elixirs, suspensions, syrups, wafers, and the like (Mathiowitz et ah, 1997; Hwang et al, 1998; U.S. Pat. Nos. 5,641,515; 5,580,579 and 5,792, 451, each specifically incorporated herein by reference in its entirety).
- the tablets, troches, pills, capsules and the like may also contain the following: a binder, such as, for example, gum tragacanth, acacia, cornstarch, gelatin or combinations thereof; an excipient, such as, for example, dicalcium phosphate, mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate or combinations thereof; a disintegrating agent, such as, for example, corn starch, potato starch, alginic acid or combinations thereof; a lubricant, such as, for example, magnesium stearate; a sweetening agent, such as, for example, sucrose, lactose, saccharin or combinations thereof; a flavoring agent, such as, for example peppermint, oil of wintergreen, cherry flavoring, orange flavoring, etc.
- a binder such as, for example, gum tragacanth, acacia, cornstarch, gelatin or combinations thereof
- an excipient such as, for
- the dosage unit form When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar, or both. When the dosage form is a capsule, it may contain, in addition to materials of the above type, carriers such as a liquid carrier. Gelatin capsules, tablets, or pills may be enterically coated. Enteric coatings prevent denaturation of the composition in the stomach or upper bowel where the pH is acidic. See, e.g., U.S. Pat. No. 5,629,001.
- the basic pH therein dissolves the coating and permits the composition to be released and absorbed by specialized cells, e.g., epithelial enterocytes and Peyer's patch M cells.
- a syrup of elixir may contain the active compound sucrose as a sweetening agent methyl and propylparabens as preservatives, a dye and flavoring, such as cherry or orange flavor.
- any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed.
- the active compounds may be incorporated into sustained-release preparation and formulations.
- compositions of the present invention may alternatively be incorporated with one or more excipients in the form of a mouthwash, dentifrice, buccal tablet, oral spray, or sublingual orally- administered formulation.
- a mouthwash may be prepared incorporating the active ingredient in the required amount in an appropriate solvent, such as a sodium borate solution (Dobell's Solution).
- the active ingredient may be incorporated into an oral solution such as one containing sodium borate, glycerin and potassium bicarbonate, or dispersed in a dentifrice, or added in a therapeutically- effective amount to a composition that may include water, binders, abrasives, flavoring agents, foaming agents, and humectants.
- the compositions may be fashioned into a tablet or solution form that may be placed under the tongue or otherwise dissolved in the mouth.
- suppositories are solid dosage forms of various weights and shapes, usually medicated, for insertion into the rectum. After insertion, suppositories soften, melt or dissolve in the cavity fluids.
- traditional carriers may include, for example, polyalkylene glycols, triglycerides or combinations thereof.
- suppositories may be formed from mixtures containing, for example, the active ingredient in the range of about 0.5% to about 10%, and preferably about 1% to about 2%.
- modulators of NCc aATP channel (antagonist and/or agonist) or related-compounds may be administered via a parenteral route.
- parenteral includes routes that bypass the alimentary tract.
- the pharmaceutical compositions disclosed herein may be administered for example, but not limited to intravenously, intradermally, intramuscularly, intraarterially, intraventricularly, intrathecally, subcutaneous, or intraperitoneally U.S. Pat. Nos. 6,7537,514, 6,613,308, 5,466,468, 5,543,158; 5,641,515; and 5,399,363 (each specifically incorporated herein by reference in its entirety).
- Solutions of the active compounds as free base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (U.S.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, DMSO, polyol (i.e., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils.
- Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- a coating such as lecithin
- surfactants for example, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium sorbic acid, thimerosal, and the like.
- isotonic agents for example, sugars or sodium chloride.
- Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
- aqueous solutions for parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
- aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration.
- sterile aqueous media that can be employed will be known to those of skill in the art in light of the present disclosure.
- one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences” 15th Edition, pages 1035- 1038 and 1570-1580).
- Some variation in dosage will necessarily occur depending on the condition of the subject being treated.
- the person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
- preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologies standards.
- Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile- filtered solution thereof.
- a powdered composition is combined with a liquid carrier such as, e.g., water or a saline solution, with or without a stabilizing agent.
- the active compound modulators of NCcaATP channel (antagonist and/or agonist) or related-compounds may be formulated for administration via various miscellaneous routes, for example, topical (i.e., transdermal) administration, mucosal administration (intranasal, vaginal, etc.) and/or inhalation.
- compositions for topical administration may include the active compound formulated for a medicated application such as an ointment, paste, cream or powder.
- Ointments include all oleaginous, adsorption, emulsion and water-solubly based compositions for topical application, while creams and lotions are those compositions that include an emulsion base only.
- Topically administered medications may contain a penetration enhancer to facilitate adsorption of the active ingredients through the skin. Suitable penetration enhancers include glycerin, alcohols, alkyl methyl sulfoxides, pyrrolidones and luarocapram.
- compositions for topical application include polyethylene glycol, lanolin, cold cream and petrolatum as well as any other suitable absorption, emulsion or water-soluble ointment base.
- Topical preparations may also include emulsifiers, gelling agents, and antimicrobial preservatives as necessary to preserve the active ingredient and provide for a homogenous mixture.
- Transdermal administration of the present invention may also comprise the use of a "patch".
- the patch may supply one or more active substances at a predetermined rate and in a continuous manner over a fixed period of time.
- the pharmaceutical compositions may be delivered by eye drops, intranasal sprays, inhalation, and/or other aerosol delivery vehicles.
- Methods for delivering compositions directly to the lungs via nasal aerosol sprays has been described e.g., in U.S. Pat. Nos. 5,756,353 and 5,804,212 (each specifically incorporated herein by reference in its entirety).
- the delivery of drugs using intranasal microparticle resins Takenaga et ah, 1998) and lysophosphatidyl-glycerol compounds (U.S. Pat. No. 5,725, 871, specifically incorporated herein by reference in its entirety) are also well-known in the pharmaceutical arts.
- transmucosal drug delivery in the form of a polytetrafluoroetheylene support matrix is described in U.S. Pat. No. 5,780,045 (specifically incorporated herein by reference in its entirety).
- aerosol refers to a colloidal system of finely divided solid of liquid particles dispersed in a liquefied or pressurized gas propellant.
- the typical aerosol of the present invention for inhalation will consist of a suspension of active ingredients in liquid, propellant or a mixture of liquid propellant and a suitable solvent.
- Suitable propellants include hydrocarbons and hydrocarbon ethers.
- Suitable containers will vary according to the pressure requirements of the propellant.
- Administration of the aerosol will vary according to subject's age, weight and the severity and response of the symptoms.
- compositions described herein may be comprised in a kit.
- a compound that selectively binds to or identifies SURl may be comprised in a diagnositc kit.
- Such compounds can be referred to as an "SURl marker", which may include, but are not limited to antibodies (monoclonal or polyclonal), SURl oligonucleotides, SURl polypeptides, small molecule or combinations thereof, antagonist, agonist, etc. It is envisioned that any of these SURl markers may be linked to a radioactive substance and/or a fluorescent marker and/or a enzymatic tag for quick determination.
- the kits may also comprise, in suitable container means a lipid, and/or an additional agent, for example a radioactive or enzymatic or florescent marker.
- kits may comprise a suitably aliquoted SURl marker, lipid and/or additional agent compositions of the present invention, whether labeled or unlabeled, as may be used to prepare a standard curve for a detection assay.
- the components of the kits may be packaged either in aqueous media or in lyophilized form.
- the container means of the kits will generally include at least one vial, test tube, flask, bottle, syringe or other container means, into which a component may be placed, and preferably, suitably aliquoted. Where there are more than one component in the kit, the kit also will generally contain a second, third or other additional container into which the additional components may be separately placed. However, various combinations of components may be comprised in a vial.
- kits of the present invention also will typically include a means for containing the SURl marker, lipid, additional agent, and any other reagent containers in close confinement for commercial sale.
- Such containers may include injection or blow molded plastic containers into which the desired vials are retained.
- kits of the present invention are kits comprising an antagonist, agonist or an related-compound thereof.
- the kit may comprise an SURl antagonist or related-compound thereof to block and/or inhibit the NCcaATP channel or the kit may comprise an SURl agonist or related- compound thereof to open the NCcaATP channel.
- Such kits will generally contain, in suitable container means, a pharmaceutically acceptable formulation of SURl antagonist, agonist or related-compound thereof.
- the kit may have a single container means, and/or it may have distinct container means for each compound.
- the liquid solution is an aqueous solution, with a sterile aqueous solution being particularly preferred.
- the SURl antagonist, agonist or related-compounds thereof may also be formulated into a syringeable composition, hi which case, the container means may itself be a syringe, pipette, and/or other such like apparatus, from which the formulation may be applied to an infected area of the body, injected into an animal, and/or even applied to and/or mixed with the other components of the kit.
- aqueous solutions include, but are not limited to ethanol, DMSO and/or Ringer's solution, hi certain embodiments, the concentration of DMSO or ethanol that is used is no greater than 0.1% or (1 ml/ 1000 L).
- the components of the kit may be provided as dried powder(s).
- the powder can be reconstituted by the addition of a suitable solvent. It is envisioned that the solvent may also be provided in another container means.
- the container means will generally include at least one vial, test tube, flask, bottle, syringe and/or other container means, into which the SURl antagonist, agonist or related- compounds thereof is suitably allocated.
- the kits may also comprise a second container means for containing a sterile, pharmaceutically acceptable buffer and/or other diluent.
- kits of the present invention will also typically include a means for containing the vials in close confinement for commercial sale, such as, e.g., injection and/or blow-molded plastic containers into which the desired vials are retained.
- a means for containing the vials in close confinement for commercial sale such as, e.g., injection and/or blow-molded plastic containers into which the desired vials are retained.
- kits of the invention may also comprise, and/or be packaged with, an instrument for assisting with the injection/administration and/or placement of the SURl antagonist, agonist or related-compounds thereof within the body of an animal.
- an instrument may be a syringe, pipette, forceps, and/or any such medically approved delivery vehicle.
- kits may also include a second active ingredient.
- the second active ingredient include substances to prevent hypoglycemia (e.g., glucose, D5W, glucagon, etc.), thrombolytic agents, anticoagulants, antiplatelets, statins, diuretics, vasodilators, etc.
- hypoglycemia e.g., glucose, D5W, glucagon, etc.
- thrombolytic agents e.g., thrombolytic agents
- anticoagulants e.g., antiplatelets
- statins e.g., statins, diuretics, vasodilators, etc.
- kits of the present invention can also include glucose testing kits.
- the blood glucose of the patient is measured using the glucose testing kit, then the SURl antagonist, agonist or related-compounds thereof can be administered to the subject followed by measuring the blood glucose of the patient.
- kits of the present invention can be assembled such that an IV bag comprises a septum or chamber which can be opened or broken to release the compound into the FV bag.
- kits may include a bolus kit in which the bolus kit comprises a pre-loaded syringe or similar easy to use, rapidly administrable device.
- An infusion kit may comprise the vials or ampoules and an IV solution (e.g., Ringer's solution) for the vials or ampoules to be added prior to infusion.
- the infusion kit may also comprise a bolus kit for a bolus/loading dose to be administered to the subject prior, during or after the infusion.
- a characteristic feature of KA T? channels is that channel affinity for ATP is modulated by the presence of the membrane lipid, PIP 2 .
- the open-state stability of KAT P channels is increased by application of PIP 2 to the cytoplasmic side of the membrane (Ashcroft, 1998; Baukrowitz et al, 1998; Rohacs et al, 1999).
- An increase in the open-state stability is manifested as an increase in the channel open probability in the absence of ATP, and in a corresponding decrease in sensitivity to inhibition by ATP (Enkvetchakul et al, 2000; Haruna et al, 2000; Koster et al, 1999; and Larsson et al, 2000).
- the standard model involved placing a stab injury into the parietal lobe of an anesthetized rat and implanting a sterile foreign body (gelatin sponge; Gelfoam®) into the stab wound.
- Variants of the standard model included impregnating the sponge with a substance (e.g., lipopolysaccharide, LPS) or infusing a substance continuously in vivo using an osmotic mini- pump with the delivery catheter placed directly into the sponge.
- a substance e.g., lipopolysaccharide, LPS
- LPS lipopolysaccharide
- the sponge itself was gently removed from the brain, the inner zone of the gliotic capsule adheres to the sponge and was excised along with it.
- the sponge was assayed for protein (e.g., Western) or mRNA (RT-PCR), or it was enzymatically dissociated to yield constituent cells for electrophysiological or other single-cell measurements.
- the gliotic capsule was well developed 7-10 days after injury.
- the gliotic capsule was visualized in coronal sections by perfusing the animal with Evans Blue prior to perfusion-fixation of the brain (FIG. 5A).
- a region of edema (dark) was seen to outline the avascular gliotic capsule (light) that surrounded the gelatin sponge (dark).
- Immunohistochemical examination with anti-GFAP antibodies showed that the brain parenchyma in the vicinity of the sponge harbors many GFAP-positive reactive astrocytes (FIG. 5B; arrow showed where the gelatin sponge was).
- FIG. 5C Intraparenchymal GFAP-positive cells were shown to be large and to bear many prominent cell processes (FIG. 5C, arrow).
- Examining the gelatin sponge itself showed GFAP-positive reactive astrocytes that migrated into the interstices of the sponge (FIG. 5D, arrow).
- Microglia were not prominent in the inner zone of the gliotic capsule itself, as indicated by sparse labeling for OX- 42.
- Cells of the inner zone of the gliotic capsule were negative for the O2A progenitor marker, A2B5, and the fibroblast marker, prolyl 4-hydroxylase (Dalton et at, 2003).
- Glibenclamide binds to sulfonylurea receptors, SURl and SUR2, with higher affinity for SURl.
- Immunofluorescence studies were performed using anti-SURx antibodies.
- the inner zone of the gliotic capsule immediately outside of the gelatin sponge (gf in FIG. 7) was strongly labeled with anti-SURl antibody (FIG. 8A) but not with anti-SUR2 antibody (FIG. 7B). Although individual cells were not discerned at low magnification, higher magnification showed that SURl label was uniformly distributed in individual cells after isolation (FIG. 7C).
- the SURl response was always located precisely at the interface with the foreign body, in the innermost zone of the gliotic capsule.
- Cells that were SURl positive were always GFAP positive. It was evident from this experiment that cells clinging to the gelatin sponge and that were harvested with it were likeliest to express SURl. Also, it was clear that Rl astrocytes in this innermost region comprised a unique subpopulation of reactive astrocytes. From this observation emerged the concept of the "inner zone" of the gliotic capsule as being a unique entity, distinct from the remainder of the gliotic capsule.
- the histochemical marker pimonidazole
- pimonidazole which at p ⁇ 2 ⁇ 10 mm Hg, forms irreversible covalent adducts with cellular proteins that can be detected immunohistochemically (Arteel et al, 1998; Hale et al., 2002; Kennedy et al, 1997).
- rats were prepared with a stab injury and implantation of a gelatin sponge. Rats were allowed to survive 1 week. Pimonidazole was administered prior to death, and cryosections were processed for immunofluorescence study using the appropriate antibody to detect pimonidazole adducts. Cryosections were double labeled for GFAP.
- This experiment confirmed the presence of hypoxic conditions restricted to the SURl -positive inner zone of the gliotic capsule, with the most prominent pimonidazole labeling extending only 20-50 ⁇ m deep (FIG. 8B; GFAP not shown but the depth of the GFAP response resembled that in FIG. 8A). High resolution imaging showed that pimonidazole labeling (FIG. 8 G, upper right) was present in large GF AP -positive astrocytes (FIG. 8G, lower left).
- HIF-I hypoxia-responsive transcription factor
- the inner zone of the gliotic capsule with its Rl astrocytes that express SURl -regulated NCc a - ATP channels and tight junction proteins, may be acting as an important barrier between the foreign body and the brain, e.g., a foreign body-brain barrier (FbBB). If true, one would expect that breaching the barrier might significantly affect the overall response to injury.
- FbBB foreign body-brain barrier
- Rats were prepared with a stab injury and implantation of a gelatin sponge according to our usual protocol and were allowed to survive 1 week. At time of surgery, rats were also implanted with osmotic mini-pumps subcutaneously with the delivery catheter placed in the brain at the site of injury. Animals received pumps with either glibenclamide (1 ⁇ M at 0.5 ⁇ l/hr x 7 days) or diazoxide (10 ⁇ M at 0.5 ⁇ l/hr x 7 days). No systemic toxicity was observed, neurological behavior was not impaired, and animals appeared healthy and were not febrile.
- Tissues were obtained from the 3 rat models (trauma, abscess and stroke) and from human metastatic tumor, and double immunolabeling was performed with antibodies directed against GFAP and SURl.
- Low power views showed a layer of tissue adjacent to the gelatin sponge implant with positive immunolabeling for GFAP that coincided with positive immunolabeling for SURl (FIG. HA 5 B)- Examination of individual cells at high power showed that the SURl immunolabel was present in large stellate-shaped astrocytes, confirming the presence of SURl -positive Rl astrocytes in the inner zone of the gliotic capsule surrounding a foreign body implant (FIG. HC).
- a brain abscess model in the rat was studied.
- the abscess was produced by implanting an autologous fecal pellet subcortically under general anesthesia. These animals survived quite well, although they showed evidence of mild weight loss.
- a purulent cavity was found surrounded by a gliotic capsule.
- Low power views of the gliotic capsule adjacent to the area of puss showed cells with positive immunolabeling for GFAP that coincided with positive immunolabeling for SURl (FIG. HD 5 E).
- a standard stoke model in the rat was studied.
- the stroke was produced by intra-carotid insertion of a thread up to the bifurcation of the internal carotid artery, placed under general anesthesia. Animals surviving the stroke were sacrificed at 1 week and the brain was examined. Low power views of tissues adjacent to the area of stroke showed cells with positive immunolabeling for GFAP that coincided with positive immunolabeling for SURl (FIG. 1 IG 5 H). Examination of individual cells at high power showed that the SURl immunolabel was present in large stellate-shaped astrocytes, confirming the presence of SURl -positive Rl astrocytes in the gliotic capsule surrounding stroke (FIG. 1 II).
- Tissue was obtained from humans undergoing surgery for resection of metastatic brain tumors.
- the gliotic capsule that surrounds the metastasis is readily distinguished from the tumor itself and from edematous white matter.
- Low power views of the gliotic capsule adjacent to the metastasis showed cells with positive immunolabeling for GFAP that coincided with positive immunolabeling for SURl (FIG. 11J,K).
- Examination of individual cells at high power showed that the SURl immunolabel was present in large stellate-shaped astrocytes with multiple well-developed processes, confirming the presence of SURl -positive Rl astrocytes in the gliotic capsule surrounding metastatic brain tumor in humans (FIG. 1 IL).
- NCc a - ATP channels were studied in a rodent model of stroke.
- SURl labeling was found in stellate-shaped cells (FIG. 12A) that were also GFAP-positive.
- stellate cells were absent, but SURl labeling was found in round cells exhibiting a bleb-like appearance (FIG. 12B,C) that were also GFAP-positive (not shown).
- the round cells with blebbing in situ resembled reactive astrocytes in vitro undergoing necrotic death after exposure to Na azide. The effect of glibenclamide vs. saline was determined.
- Glibenclamide or saline was administered via subcutaneously-implanted osmotic mini-pump (1 ⁇ M at 0.5 ⁇ l/hr).
- 3-day mortality after stroke was 68%
- SURl was also studied in a rodent model of trauma.
- the effect of direct infusion of drugs into the site of trauma was examined using an implanted osmotic mini-pump.
- the channel inhibitor, glibenclamide was used to reduce death of reactive astrocytes, and the channel activator, diazoxide, to promote astrocyte death.
- Glibenclamide infusion reduced the overall injury response, stabilized the gliotic capsule around the foreign body implant, and minimized the inflammatory response compared to control.
- NCc a -A ⁇ p channel plays a critical role in the injury response, and they strongly support the hypothesis that inflammation is closely linked to activity of the NCc a - ATP channel and necrotic death of reactive astrocytes.
- thromboembolic (TE) stroke 7-8 allogeneic clots, 1.5 mm long, were embolized. Allogeneic, thrombin-induced, fibrin-rich blood clots were prepared (Toomy et al, 2002).
- MCA strokes with malignant cerebral edema the inventors first embolized microparticles (Nakabayashi et al, 1997) [polyvinyl alcohol (PVA) particles; Target Therapeutics, Fremont CA; 150-250 ⁇ m diameter, 600 ⁇ g in 1.5 ml heparinized-saline], followed by standard permanent intraluminal suture occlusion (Kawamura et al, 1991) using a monofilament suture (4-0 nylon, rounded at the tip and coated with poly-L-lysine) advanced up to the ICA bifurcation and secured in place with a ligature.
- PVA polyvinyl alcohol
- mini-osmotic pumps (Alzet 2002, Durect Corporation, Cupertino, CA) were implanted subcutaneously that delivered either saline or glibenclamide (Sigma, St. Louis, MO; 300 ⁇ M or 148 ⁇ g/ml, 0.5 ⁇ l/hr subcutaneously, no loading dose).
- Stroke size (TE model), measured as the volume of TTC(-) tissue in consecutive 2 mm thick slices and expressed as the percent of hemisphere volume, was compared 48 after stroke in 2 treatment groups, each comprised of 10 male rats, treated with either saline or glibenclamide.
- Mortality was compared during the first week after stroke in 2 treatment groups, each comprised of 29 rats (19 female plus 10 male), treated with either saline or glibenclamide.
- Edema was compared at 8 hr after stroke in 2 treatment groups, each comprised of 11 male rats, treated with either saline or glibenclamide; rats in each of these 2 treatment groups were subdivided into 2 subgroups, with the first of these being used to analyze water in the entire involved hemisphere (no TTC processing), and the second being used to analyze water in the TTC(+) vs. TTC(-) portions of the involved hemisphere.
- BODIPY-FL-glyburide BODIPY-FL-glyburide, Molecular Probes, Eugene, OR; 300 ⁇ M or 235 ⁇ g/ml, 0.5 ⁇ l/hr subcutaneously, no loading dose.
- 15 rats were used for validation of drug action (mortality, tissue water and glucose) and 5 rats were used for determination of drug distribution.
- Tissue water was quantified by the wet/dry weight method (Hua et ah, 2003). Tissue samples were blotted to remove small quantities of adsorbed fluid. Samples were weighed with a precision scale to obtain the wet weight (WW), dried to constant weight at 80° C and low vacuum, and then reweighed to obtain the dry weight (WD). The percent H 2 O of each tissue sample was then calculated as (WW-WD)x 100/WW.
- Tissues lysates and gels were prepared (Perillan et al, 2002). Membranes were developed for SURl (SC-5789; Santa Cruz Biotechnology), Kir ⁇ .l (Santa Cruz) or Kir6.2 (Santa Cruz). Membranes were stripped and re-blotted for ⁇ -actin (1:5000; Sigma, St. Louis, MO), which was used to normalize the primary data. Detection was carried out using the ECL system (Amersham Biosciences, Inc.) with routine imaging and quantification (Fuji LAS-3000).
- Non-radioactive digoxigenin-labeled probes were made according to the manufacturer's protocol (Roche) using SP6 or T7 RNA polymerase.
- RNA dig-labeled probes (sense and anti-sense) were generated from pGEM-T easy plasmids (Promega) with the SURl insert (613 bp) flanked by the primers: 5' AAGCACGTCAACGCCCT 3' (forward); 5' GAAGCTTTTCCGGCTTGTC 3' (reverse).
- Fresh-frozen (10 ⁇ m) or paraffin-embedded (4 ⁇ m) sections of rat brain (3, 6, 8 hours after MCA stroke) were used for in situ hybridization (Anisimov et al, 2002).
- the MCE model was used to evaluate SURl protein and mRNA, and to assess effects of SURl inhibition on edema and survival, while the TE model was used to measure effects of SURl inhibition on stroke size. Absence of perfusion (FIG. 14A), TTC staining (Mathews et al, 2000) (FIG. 14B) and GFAP immunolabeling were used to distinguish infarct from peri-infarct regions. [0336] SURl expression increased transiently in the core of the infarct. Here, an increase in SURl became evident as early as 2-3 hr after MCA occlusion (FIG.
- FIG. 15A-G of the showed that SURl was significantly up-regulated in stroke. It also showed that the pore-forming subunits, Kir ⁇ .l and Kir6.2, were not up-regulated in stroke, suggesting that KA TP channels were not involved.
- SURl up-regulation is due to NCc a - A ⁇ p channels and not to KATP channels.
- patch clamp recordings of neurons and endothelial cells from ischemic regions were performed. Large neuron-like cells were enxymatically isolated 3-hr (FIG. 16A) and 6-hr after stroke. Patch clamp study was carried out using Cs + in the bath and pipette, to block all K + channels including K ATP channels.
- glibenclamide had been shown to ameliorate cytotoxic edema of astrocytes induced by energy depletion (Chen et al, 2003), it was reasoned that the beneficial effect on mortality was related to edema.
- the effect of glibenclamide on the formation of edema 8 hr after induction of stroke (MCE model) was examined. This is a time that preceded death of any animal in the mortality study.
- water content in the involved and uninvolved hemispheres was measured using the methods described in Example 14. For the control hemisphere, water was 77.9+0.2%.
- TE non-lethal thromboembolic
- the fluorescent derivative BODIPY-glibenclamide
- MCE model The fluorescent derivative, BODIPY-glibenclamide
- the low systemic dose of drug used yielded minimal labeling in the uninvolved hemisphere (FIG.
- FIG. 18B pancreas, and none in the unperfused core of the stroke.
- FIG. 18A cells in peri-infarct regions were clearly labeled, with well-defined labeling of large neuron-like cells and of microvessels (FIG. 18A), including capillaries (FIG. 18C), that showed prominent expression of SURl (FIG. 18D).
- Preferential cellular labeling in ischemic brain likely reflected not only an increase in glibenclamide binding sites, but also an increase in uptake, possibly due to alteration of the blood brain barrier.
- NCc a - ATP channels were found in capillary endothelium and neurons in addition to their previously described presence in astrocytes (Chen et al, 2001; Chen et al, 2003).
- Additional patch clamp experiments on neurons and microvessels isolated from ischemic cortex 1-6 hr after MCA occlusion (MCE model) confirmed the presence of NCc a - ATP channels, showing a non-selective cation channel of around 30-35 pS conductance, that was easily recorded with Cs + as the charge carrier, and that was blocked by glibenclamide. This channel was not present in cells from non-ischemic cerebral tissues.
- a rodent model of thromboembolic stroke was used (Aoki et al, 2002; Kijkhuizen et al, 2001; Kano et al, 2000; Sumii et al, 2002; Tejima et al, 2001). Briefly, male spontaneously hypertensive rats that have been fasted overnight are anesthetized using halothane (1-1.5% in a 70/30 mixture of N 2 O/O 2 ) with spontaneous respiration (Lee et al, 2004; Sumii et al, 2002). Rectal temperature was maintained at ⁇ 37°C with a thermostat-controlled heating pad.
- the right femoral artery was cannulated, and physiological parameters, including temperature, mean blood pressure, pH, p ⁇ 2 , and pCO 2 , glucose were monitored.
- Temporary focal ischemia was obtained with an embolic model that used allogeneic clots to occlude the MCA. Allogeneic, thrombin-induced, fibrin-rich blood clots were prepared using methods adapted from Miessen et al. (Asahi et al, 2000; Niessen et al, 2003; Sumii et al, 2002). Seven clots, 1.5 mm long, were used for embolizing.
- a mini-osmotic pump (Alzet 2002, Durect Corporation, Cupertino, CA) was implanted subcutaneously that delivered either saline or glibenclamide (300 ⁇ M or 148 ⁇ g/ml, 0.5 ⁇ l/hr s.q.).
- Physiological parameters including temperature, mean blood pressure (tail cuff plethysmography), blood gases and glucose were monitored.
- Animals were euthanized 24 hr following stroke and brains were perfused to remove blood from the intravascular compartment. Coronal sections of the fresh brains were prepared and photographed, following which sections were processed for TTC staining to identify areas of infarction.
- microvessels were adhered to the side of the container with a magnet and washed repeatedly to remove enzyme and cellular debris.
- Isolated endothelial cells were studied using freshly isolated endothelial cells using a nystatin-perforated patch technique. With physiological solutions, the cells exhibited a prominent, strongly rectifying inward current at negative potentials, and a modest outward current at positive potentials (FIG. 22A), yielding a characteristic current-voltage curve with near-zero current at intermediate potentials (FIG. 22C), similar to previous observations in freshly isolated endothelial cells (Hogg et al., 2002). When K + in the pipette solution was replaced with Cs + , K + channel currents were completely blocked. In endothelial cells, this yielded a current- voltage curve that was linear (FIG. 22E). These data demonstrated that voltage dependent channels in freshly isolated endothelial cells are exclusively K + channels that do not carry Na + .
- Cryosections (10 ⁇ m) were used for TTC staining (Mathews et al, 2000) or alternatively, high-contrast silver infarct staining (SIS), (Vogel et al, 1999) to identify the region of ischemia, and for immunolabeling, to verify SURl u ⁇ -regulation in neurons double labeled for NeuN.
- Vibratome sections 300 ⁇ m were processed (Hainsworth et al, 2000; Kay et al, 1986; Moyer et al, 1998) to obtain single neurons for patch clamping. Selected portions of coronal slices were incubated at 35° C in HBSS bubbled with air.
- the pieces were transferred to HBSS containing 1.5 mg/ml protease XIV (Sigma). After 30-40 min of protease treatment, the pieces were rinsed in enzyme-free HBSS and mechanically triturated.
- enzyme-free HBSS For controls, cells from mirror-image cortical areas in the uninvolved hemisphere were used. Cells were allowed to settle in HBSS for 10-12 min in a plastic Petri dish mounted on the stage of an inverted microscope. Large and medium-sized pyramidal-shaped neurons were selected for recordings. At this early time of 2-3 hr, only neurons and capillaries, not astrocytes, show up-regulation of SURl.
- Activation of MMP-9 & MMP -2 in stroke tissue was compared to controls. Briefly, gelatinase activity of recombinant enzyme and stroke tissue under control conditions (CTR), in presence of glibenclamide (10 ⁇ M), and in presence of MMP-inhibitor It (300 nM; Calbiochem). [0365] Next, the supernatants underwent a gelatinase purification process with gelatin- Sepharose 4B (Pharmacia), and Zymography was performed on the purified supernatants in sodium dodecyl sulfate gels containing gelatin (Rosenberg, 1994). Dried gels were scanned with a transparency scanner, and images were analyzed by densitometry. The relative lysis of an individual sample was expressed as the integrated density value of its band and divided by the protein content of the sample.
- CTR homogenized brain tissues contralateral
- STROKE ipsilateral to MCAO
- cDNA was synthesized with 4 ⁇ g of total RNA per 50 ⁇ l of reaction mixture using TaqMan RT kit (Applied Biosystems). Relative values of SURl-mRNA were obtained by normalizing to HIfO (histone 1 member 0).
- SURl expression was "knocked down" in situ by infusing oligodeoxynucleotide (ODN) for 14 days using a mini-osmotic pump, with the delivery catheter placed in the gelfoam implantation site in the brain, in the otherwise standard model we use for Rl astrocyte isolation (Perillan et al, 1980, Perillan et al, 2002, Perillan et al, 2000, Perillan et al, 1999).
- ODN oligodeoxynucleotide
- SURlKD Knockdown of SURl expression was achieved using antisense (AS; 5 I -GGCCGAGTGGTTCTCGGT-3 1 ) (Yokoshiki et al, 1999) oligodeoxynucleotide (ODN), with scrambled (SCR; S'-TGCCTGAGGCGTGGCTGT-S') ODN being used as control.
- AS antisense
- ODN oligodeoxynucleotide
- SCR scrambled
- the inventors enzymatically isolated single cells from SURlKD and controls using a standard cell isolation protocols described above (Chen et al, 2003) to assess functional responses to ATP depletion induced by Na azide.
- Na azide (1 mM) caused rapid depolarization due to Na influx attributable to activation of NCc a - ATP channels (FIG. 24C).
- this depolarizing response was opposite the hyperpolarizing response observed when K ATP channels were activated.
- Na azide had little effect on resting membrane potential (FIG. 24D).
- application of Na azide resulted in depolarization of 64 ⁇ 3.7 mV, whereas in cells for SURlKD, depolarization was only 8.7 ⁇ 1.7 mV (FIG. 24E).
- SPl was prominently expressed in large neuron-like cells and in capillaries (FIG. 25 A, 25C) in regions confirmed to be ischemic by virtue of expression of HIFl ⁇ (FIG. 25B). Notably, capillaries that expressed SPl also showed prominent expression of SURl (FIG. 25C, 25D). Contralateral control tissues showed little immunolabeling for SPl and none for HIFl ⁇ (FIG. 25E, 25F).
- Nuclear SPl localization was significantly augmented early-on in stroke (FIG. 26A, 26B), and nuclear SPl was found in large neuron-like cells that express SURl following MCAO (FIG. 26C).
- HIF l ⁇ knock-down animals were obtained by infusion of antisense oligodeoxynucleotide at the site of gelfoam implant.
- FIG. 27 confirms the HIFl ⁇ knock-down animals results in a significant decrease in SURl expression (FIG. 27B, 27D), providing strong evidence that not only SPl but also HIF l ⁇ is likely to be an important regulator of SURl expression.
- Hale LP et al, Am J Physiol Heart Circ Physiol. 2002;282:H1467-H1477.
- Wiesener MS et al, FASEB J. 2003;17:271-273.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005290238A AU2005290238A1 (en) | 2004-09-18 | 2005-07-25 | Therapeutic agents trageting the NCCa-ATP channel and methods of use thereof |
EP05805849A EP1802313B1 (en) | 2004-09-18 | 2005-07-25 | Therapeutic agents trageting the ncca-atp channel and methods of use thereof |
US11/574,793 US10583094B2 (en) | 2004-09-18 | 2005-07-25 | Therapeutic methods that target the NCCA-ATP channel |
JP2007532321A JP5307397B2 (en) | 2004-09-18 | 2005-07-25 | Therapeutic agent targeting NCCa-ATP channel and method of use thereof |
DE602005024597T DE602005024597D1 (en) | 2004-09-18 | 2005-07-25 | THERAPEUTIC AGENTS FOR TARGETING THE NCCA ATP CHANNEL AND USE METHOD THEREFOR |
CA2583397A CA2583397C (en) | 2004-09-18 | 2005-07-25 | Therapeutic agents targeting the ncca-atp channel and methods of use thereof |
AT05805849T ATE486606T1 (en) | 2004-09-18 | 2005-07-25 | THERAPEUTIC AGENTS FOR TARGETING THE NCCA ATP CHANNEL AND METHOD OF USE THEREOF |
IL181740A IL181740A0 (en) | 2004-09-18 | 2007-03-06 | THERAPEUTIC AGENTS TARGETING THE NCca-atp CHANNEL AND METHODS OF USE THEREOF |
US16/752,301 US20200163902A1 (en) | 2004-09-18 | 2020-01-24 | THERAPEUTIC AGENTS TARGETING THE NCCa-ATP CHANNEL AND METHODS OF USE THEREOF |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61075804P | 2004-09-18 | 2004-09-18 | |
US60/610,758 | 2004-09-18 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/574,793 A-371-Of-International US10583094B2 (en) | 2004-09-18 | 2005-07-25 | Therapeutic methods that target the NCCA-ATP channel |
US16/752,301 Continuation US20200163902A1 (en) | 2004-09-18 | 2020-01-24 | THERAPEUTIC AGENTS TARGETING THE NCCa-ATP CHANNEL AND METHODS OF USE THEREOF |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2006036278A2 true WO2006036278A2 (en) | 2006-04-06 |
WO2006036278A3 WO2006036278A3 (en) | 2007-02-22 |
WO2006036278A8 WO2006036278A8 (en) | 2007-05-18 |
Family
ID=36119325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/026455 WO2006036278A2 (en) | 2004-09-18 | 2005-07-25 | THERAPEUTIC AGENTS TARGETING THE NCCa-ATP CHANNEL AND METHODS OF USE THEREOF |
Country Status (10)
Country | Link |
---|---|
US (2) | US10583094B2 (en) |
EP (3) | EP2359832A3 (en) |
JP (2) | JP5307397B2 (en) |
CN (2) | CN101043891A (en) |
AT (1) | ATE486606T1 (en) |
AU (1) | AU2005290238A1 (en) |
CA (1) | CA2583397C (en) |
DE (1) | DE602005024597D1 (en) |
IL (1) | IL181740A0 (en) |
WO (1) | WO2006036278A2 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1850663A2 (en) * | 2005-02-22 | 2007-11-07 | Cedars-Sinai Medical Center | Use of minoxidil sulfate as an anti-tumor drug |
WO2008073317A2 (en) * | 2006-12-08 | 2008-06-19 | Musc Foundation For Research Development | Cytarabine for treatment of glioma |
EP1993562A2 (en) * | 2006-02-22 | 2008-11-26 | University of Maryland, Baltimore | A novel non-selective cation channel in neuronal cells and methods for treating brain swelling |
WO2009002832A2 (en) | 2007-06-22 | 2008-12-31 | University Of Maryland, Baltimore | Inhibitors of ncca-atp channels for therapy |
JP2009055796A (en) * | 2007-08-30 | 2009-03-19 | Shionogi & Co Ltd | Model for evaluating life prolongment |
EP2111224A2 (en) * | 2007-01-12 | 2009-10-28 | University of Maryland, Baltimore | Targeting ncca-atp channel for organ protection following ischemic episode |
EP2595633A2 (en) * | 2010-07-19 | 2013-05-29 | Remedy Pharmaceuticals, Inc. | Methods of intravenous administration of glyburide and other drugs |
US9107932B2 (en) | 2002-03-20 | 2015-08-18 | University Of Maryland, Baltimore | Methods for treating neural cell swelling |
US10131784B2 (en) | 2008-09-30 | 2018-11-20 | Columbia Insurance Company | Recycled polyethylene terephthalate compositions, fibers and articles produced therefrom, and methods for producing same |
US10214643B2 (en) | 2008-09-30 | 2019-02-26 | Columbia Insurance Company | Recycled polyethylene terephthalate compositions, fibers and articles produced therefrom, and methods for producing same |
US10583094B2 (en) | 2004-09-18 | 2020-03-10 | University Of Maryland | Therapeutic methods that target the NCCA-ATP channel |
US10894055B2 (en) | 2013-11-06 | 2021-01-19 | Aeromics, Inc. | Pharmaceutical compositions, methods of making pharmaceutical compositions, and kits comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}4-chlorophenyl dihydrogen phosphate |
US11084778B2 (en) | 2012-05-08 | 2021-08-10 | Aeromics, Inc. | Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008098160A1 (en) * | 2007-02-09 | 2008-08-14 | University Of Maryland, Baltimore | Antagonists of a non-selective cation channel in neural cells |
JP2012061053A (en) | 2010-09-14 | 2012-03-29 | Yuuki Kitaoka | Administration apparatus, method of operating the same, and administration method |
US9116974B2 (en) * | 2013-03-15 | 2015-08-25 | Robert Bosch Gmbh | System and method for clustering data in input and output spaces |
CN108348567B (en) * | 2015-05-29 | 2022-03-01 | 马里兰州立大学巴尔的摩分校 | Methods for reducing or preventing intimal damage from mechanical stimulation of endothelial cells |
EP3622958B1 (en) * | 2017-05-09 | 2024-03-20 | Zhejiang University | Use of potassium ion channel inhibitor for treatment of depression and pharmaceutical composition |
CN108078999B (en) * | 2017-12-22 | 2020-08-14 | 沈阳药科大学 | Pharmaceutical composition for preventing and treating cerebral arterial thrombosis and preparation method and application thereof |
US11227692B2 (en) * | 2017-12-28 | 2022-01-18 | International Business Machines Corporation | Neuron model simulation |
US20210046094A1 (en) * | 2018-02-27 | 2021-02-18 | The United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods for treating pain |
CN108310387A (en) * | 2018-03-23 | 2018-07-24 | 昆药集团股份有限公司 | A kind of combination product and its application for preventing and/or treating cerebral ischemia |
CN110372874B (en) * | 2019-06-20 | 2021-06-11 | 东南大学 | Rare earth nano enzyme, preparation method thereof and application thereof in degrading and determining estrogen endocrine disruptors |
CN111474366A (en) * | 2020-04-02 | 2020-07-31 | 桂林医学院 | Application of Kir6.2-SUR1 as drug target for treating manganese poisoning Parkinson disease |
CN111568898A (en) * | 2020-04-23 | 2020-08-25 | 首都医科大学附属北京天坛医院 | Application of lovastatin or pharmaceutically acceptable salt thereof in preparing medicament for treating cerebral arteriovenous malformation |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
GB8809205D0 (en) | 1988-04-19 | 1988-05-25 | Nye P C G | Treatment of oedema |
US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US5166162A (en) | 1990-03-02 | 1992-11-24 | Adir Et Compagnie | Pyridylsulfonylurea and pyridylsulfonylthiourea compounds |
US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
CA2044853C (en) | 1990-07-19 | 2004-11-09 | Susan A. Greenfield | Method for treating parkinson's disease employing an atp-sensitive potassium channel blocker |
US5236932A (en) | 1990-07-19 | 1993-08-17 | E. R. Squibb & Sons, Inc. | Method for treating Parkinson's disease employing quinine |
US5215985A (en) | 1990-07-20 | 1993-06-01 | E. R. Squibb & Sons, Inc. | Method for treating ischemic insult to neurons employing an ATP-sensitive potassium channel blocker |
CA2044855A1 (en) | 1990-07-20 | 1992-01-21 | Kerry P. S. J. Murphy | Method for treating insult to neurons prone to parkinson's degeneration employing an atp-sensitive potassium channel blocker |
ATE199095T1 (en) | 1990-10-16 | 2001-02-15 | Childrens Medical Center | HEPARIN BINDING MITOGEN WITH HOMOLOGY TO THE EPIDERMIS GROWTH FACTOR (EGF) |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
ES2109362T3 (en) | 1991-06-21 | 1998-01-16 | Univ Cincinnati | ADMINISTRABLE PROTEINS ORALLY AND METHOD TO MAKE THEM. |
US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
US5916871A (en) | 1992-04-27 | 1999-06-29 | Kansas State University Research Foundation | Inhibitory factor |
WO1993023011A1 (en) | 1992-05-18 | 1993-11-25 | Minnesota Mining And Manufacturing Company | Transmucosal drug delivery device |
US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
US6071970A (en) * | 1993-02-08 | 2000-06-06 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US6350739B1 (en) | 1999-08-11 | 2002-02-26 | University Of Florida Resarch Foundation, Inc. | Methods of prevention and treatment of ischemic damage |
DE4430212A1 (en) | 1994-08-28 | 1996-02-29 | Merck Patent Gmbh | Ortho-substituted benzoic acid derivatives |
US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
US20010003751A1 (en) | 1995-02-22 | 2001-06-14 | Terashita Zen-Ichi | Pharmaceutical composition for treating transient ischemic attack |
AUPN193095A0 (en) | 1995-03-24 | 1995-04-27 | Polychip Pharmaceuticals Pty Ltd | Potassium ion channel blockers |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
US5545656A (en) | 1995-04-05 | 1996-08-13 | Pfizer Inc. | 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease |
US5637085A (en) | 1995-11-20 | 1997-06-10 | Cardinale; Robert M. | Method of cancer tumor treatment by slow release delivery of 1,2,4-benzotriazine oxides to tumor site |
JPH09208562A (en) | 1996-01-26 | 1997-08-12 | Ono Pharmaceut Co Ltd | Nitrogen monoxide synthetase inhibitor |
US7608262B2 (en) | 1996-02-16 | 2009-10-27 | The Kennedy Institute Of Rheumatology | Methods of preventing or treating thrombosis with tumor necrosis factor antagonists |
US5856360A (en) | 1996-05-03 | 1999-01-05 | Children's Hospital Medical Center | Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock |
EP1006798A4 (en) | 1996-09-05 | 2003-03-05 | Massachusetts Inst Technology | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
US6184248B1 (en) | 1996-09-05 | 2001-02-06 | Robert K. K. Lee | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
US20020016443A1 (en) | 1996-10-04 | 2002-02-07 | Keay Susan K. | Antiproliferative factor |
US5962645A (en) | 1996-10-04 | 1999-10-05 | University Of Maryland | Antiproliferative factor from patients with interstitial cystitis |
AU8283898A (en) | 1997-06-30 | 1999-01-25 | University Of Maryland At Baltimore | Heparin binding-epidermal growth factor in the diagnosis of interstitial cystitis |
US6679859B1 (en) | 1997-10-24 | 2004-01-20 | Alliance Pharmaceutical Corp. | Amelioration of ischemic damage using synthetic oxygen carriers |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
CA2316303A1 (en) | 1997-12-26 | 1999-07-08 | Masaki Nakamura | Suppressing agent of angiogenesis, containing dienogest as effective ingredient |
US6180671B1 (en) | 1998-03-10 | 2001-01-30 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected |
US6737514B1 (en) | 1998-12-22 | 2004-05-18 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6100047A (en) | 1999-04-07 | 2000-08-08 | Zen Bio, Inc. | Modulation of the sulfonylurea receptor and calcium in adipocytes for treatment of obesity/diabetes |
WO1999054706A2 (en) | 1998-04-17 | 1999-10-28 | Univ Maryland | Method of treating interstitial cystitis with recombinant hb-egf |
US6613785B2 (en) | 1998-07-21 | 2003-09-02 | Smithkline Beecham Plc | Use of glucose uptake enhancer for reducing post-ischemic injury of the heart |
AU771579B2 (en) | 1998-10-26 | 2004-03-25 | Avi Biopharma, Inc. | p53 antisense agent and method |
US6469130B1 (en) * | 1998-12-24 | 2002-10-22 | Kimberly-Clark Worldwide, Inc. | Synthetic fiber nonwoven web and method |
EP2314700A1 (en) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
US6391911B1 (en) | 1999-02-26 | 2002-05-21 | Robert E. Bases | Coadministration of lucanthone and radiation for treatment of cancer |
IL145732A0 (en) | 1999-04-06 | 2002-07-25 | Sankyo Co | α-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
EP1178963A1 (en) | 1999-05-12 | 2002-02-13 | Neurosearch A/S | Ion channel modulating agents |
YU23802A (en) | 1999-09-30 | 2004-09-03 | Neurogen Corporation | Certain alkylene diamine-substituted pyrazolo/1,5-a/1,5- pyrimidines and pyrazolo/1,5-a/-1,3,5-triazines |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
AU777776B2 (en) | 1999-12-23 | 2004-10-28 | Novartis Ag | Use of hypoglycemic agent for treating impaired glucose metabolism |
WO2001054680A2 (en) * | 2000-01-26 | 2001-08-02 | Cedars-Sinai Medical Center | Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor |
AU2001245793A1 (en) | 2000-03-16 | 2001-09-24 | Cold Spring Harbor Laboratory | Methods and compositions for rna interference |
ATE266409T1 (en) | 2000-04-13 | 2004-05-15 | Pfizer Prod Inc | SYNERGISTIC EFFECT OF GLYBURIDE AND MILRINONE |
US6653332B2 (en) | 2000-05-03 | 2003-11-25 | Tularik Inc. | Combination therapeutic compositions and method of use |
EP1282444B1 (en) * | 2000-05-15 | 2006-11-22 | SmithKline Beecham Corporation | Antithrombotic agents |
US6627636B2 (en) | 2000-06-15 | 2003-09-30 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
DE10054481A1 (en) | 2000-11-03 | 2002-05-08 | Aventis Pharma Gmbh | Acylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical compositions containing them |
ITMI20010450A1 (en) | 2001-03-05 | 2002-09-05 | Univ Ferrara | PROPHARMACIES DERIVED FROM ASCORBIC ACID AT THE PASSAGE OF THE BLOOD-ENCEPHALIC BARRIER |
US6492339B1 (en) | 2001-05-23 | 2002-12-10 | Insmed, Incorporated | Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof |
KR100484371B1 (en) | 2001-10-25 | 2005-04-20 | 가부시키가이샤 아텍스 | Method of manufacturing the sheet with heating wire |
WO2003057843A2 (en) | 2001-12-31 | 2003-07-17 | Algos Therapeutics, Inc. | Methods and materials for modulating trpc4 |
US20030171407A1 (en) | 2002-03-07 | 2003-09-11 | Upsher-Smith Laboratories, Inc. | Composition for reducing blood glucose and cholesterol |
JP4485806B2 (en) | 2002-03-20 | 2010-06-23 | ユニヴァーシティ オブ メリーランド,ボルチモア | Non-selective cation channels and brain swelling of neural cells |
US8980952B2 (en) | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
US20040029275A1 (en) | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
WO2004093896A1 (en) | 2003-04-22 | 2004-11-04 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage |
US7326706B2 (en) | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
WO2005041877A2 (en) | 2003-10-29 | 2005-05-12 | Children's Medical Center Corporation | Method of inhibiting rejection following organ transplantation |
WO2006000608A1 (en) | 2004-06-23 | 2006-01-05 | Neurotec Pharma, S.L. | Compounds for the treatment of an acute injury to the central nervous system |
EP2359832A3 (en) | 2004-09-18 | 2011-11-23 | University of Maryland, Baltimore | Therapeutic agents targeting the NCCA-ATP channel and methods of use thereof |
AU2005287090A1 (en) | 2004-09-18 | 2006-03-30 | Department Of Veterans Affairs | Therapeutic agents targeting the NCca-ATP channel and methods of use thereof |
AU2006269994A1 (en) | 2005-07-15 | 2007-01-25 | Children's Medical Center Corporation | Methods for treating and diagnosing complications of premature birth |
WO2007011595A2 (en) | 2005-07-15 | 2007-01-25 | Neuren Pharmaceuticals Limited | Neural regeneration peptides and antioxidants protect neurons from degeneration |
MX2008006204A (en) | 2005-11-11 | 2008-10-17 | Aurogen Inc | Method for treating disease or disorder of adult central nervous system associated with tissue shrinkage or atrophy by administration of insulin. |
EP3103451A1 (en) | 2007-01-12 | 2016-12-14 | University of Maryland, Baltimore | Targetting ncca-atp channel for organ protection following ischemic episode |
WO2008098160A1 (en) | 2007-02-09 | 2008-08-14 | University Of Maryland, Baltimore | Antagonists of a non-selective cation channel in neural cells |
CA2974689C (en) | 2007-06-22 | 2020-02-25 | The United States Of America As Represented By The Department Of Veters Affairs | Inhibitors of ncca-atp channels for therapy |
US7787809B2 (en) | 2007-09-10 | 2010-08-31 | Kabushiki Kaisha Toshiba | Image forming apparatus, transfer unit thereof, and method of shifting transfer rollers thereof |
US7813201B2 (en) | 2008-07-08 | 2010-10-12 | Atmel Corporation | Differential sense amplifier |
-
2005
- 2005-07-25 EP EP10010753A patent/EP2359832A3/en not_active Withdrawn
- 2005-07-25 AT AT05805849T patent/ATE486606T1/en not_active IP Right Cessation
- 2005-07-25 AU AU2005290238A patent/AU2005290238A1/en not_active Abandoned
- 2005-07-25 DE DE602005024597T patent/DE602005024597D1/en active Active
- 2005-07-25 CA CA2583397A patent/CA2583397C/en active Active
- 2005-07-25 JP JP2007532321A patent/JP5307397B2/en active Active
- 2005-07-25 WO PCT/US2005/026455 patent/WO2006036278A2/en active Application Filing
- 2005-07-25 CN CNA2005800359028A patent/CN101043891A/en active Pending
- 2005-07-25 US US11/574,793 patent/US10583094B2/en active Active
- 2005-07-25 EP EP05805849A patent/EP1802313B1/en active Active
- 2005-09-16 CN CN2005800360557A patent/CN101217962B/en active Active
- 2005-09-16 EP EP10010752.3A patent/EP2382977B1/en active Active
-
2007
- 2007-03-06 IL IL181740A patent/IL181740A0/en unknown
-
2011
- 2011-10-24 JP JP2011233404A patent/JP2012017346A/en active Pending
-
2020
- 2020-01-24 US US16/752,301 patent/US20200163902A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
None |
Cited By (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10533988B2 (en) | 2002-03-20 | 2020-01-14 | University Of Maryland, Baltimore | Methods for treating central or peripheral nervous system damage |
US9107932B2 (en) | 2002-03-20 | 2015-08-18 | University Of Maryland, Baltimore | Methods for treating neural cell swelling |
US8980952B2 (en) | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
US10583094B2 (en) | 2004-09-18 | 2020-03-10 | University Of Maryland | Therapeutic methods that target the NCCA-ATP channel |
EP1850663A2 (en) * | 2005-02-22 | 2007-11-07 | Cedars-Sinai Medical Center | Use of minoxidil sulfate as an anti-tumor drug |
EP1850663A4 (en) * | 2005-02-22 | 2008-03-19 | Cedars Sinai Medical Center | Use of minoxidil sulfate as an anti-tumor drug |
US7705010B2 (en) | 2005-02-22 | 2010-04-27 | Cedars-Sinai Medical Center | Use of minoxidil sulfate as an anti-tumor drug |
EP1993562A2 (en) * | 2006-02-22 | 2008-11-26 | University of Maryland, Baltimore | A novel non-selective cation channel in neuronal cells and methods for treating brain swelling |
EP1993562A4 (en) * | 2006-02-22 | 2012-07-18 | Univ Maryland | A novel non-selective cation channel in neuronal cells and methods for treating brain swelling |
WO2008073317A2 (en) * | 2006-12-08 | 2008-06-19 | Musc Foundation For Research Development | Cytarabine for treatment of glioma |
WO2008073317A3 (en) * | 2006-12-08 | 2009-04-02 | Musc Found For Res Dev | Cytarabine for treatment of glioma |
US20100143347A1 (en) * | 2007-01-12 | 2010-06-10 | The University Of Maryland, Baltimore | Targeting ncca-atp channel for organ protection following ischemic episode |
US10898496B2 (en) | 2007-01-12 | 2021-01-26 | University Of Maryland, Baltimore | Targeting NCCa-ATP channel for organ protection following ischemic episode |
US10166244B2 (en) | 2007-01-12 | 2019-01-01 | University Of Maryland, Baltimore | Targeting NCCA-ATP channel for organ protection following ischemic episode |
US9511075B2 (en) | 2007-01-12 | 2016-12-06 | The University Of Maryland, Baltimore | Targeting NCCA-ATP channel for organ protection following ischemic episode |
EP2111224A2 (en) * | 2007-01-12 | 2009-10-28 | University of Maryland, Baltimore | Targeting ncca-atp channel for organ protection following ischemic episode |
EP2111224A4 (en) * | 2007-01-12 | 2010-03-24 | Univ Maryland | Targeting ncca-atp channel for organ protection following ischemic episode |
US20220193096A1 (en) * | 2007-06-22 | 2022-06-23 | University Of Maryland, Baltimore | Inhibitors of ncca-atp channels for therapy |
US20140171467A1 (en) * | 2007-06-22 | 2014-06-19 | J. Marc Simard | Inhibitors of ncca-atp channels for therapy |
WO2009002832A2 (en) | 2007-06-22 | 2008-12-31 | University Of Maryland, Baltimore | Inhibitors of ncca-atp channels for therapy |
US8557867B2 (en) | 2007-06-22 | 2013-10-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Inhibitors of NCCa-ATP channels for therapy |
EP2167107A4 (en) * | 2007-06-22 | 2010-08-25 | Univ Maryland | Inhibitors of ncca-atp channels for therapy |
US9375438B2 (en) | 2007-06-22 | 2016-06-28 | University Of Maryland, Baltimore | Inhibitors of NCCa-ATP channels for therapy |
EP2167107A2 (en) * | 2007-06-22 | 2010-03-31 | University of Maryland, Baltimore | Inhibitors of ncca-atp channels for therapy |
US20100311639A1 (en) * | 2007-06-22 | 2010-12-09 | Simard J Marc | Inhibitors of ncca-atp channels for therapy |
JP2009055796A (en) * | 2007-08-30 | 2009-03-19 | Shionogi & Co Ltd | Model for evaluating life prolongment |
US10131784B2 (en) | 2008-09-30 | 2018-11-20 | Columbia Insurance Company | Recycled polyethylene terephthalate compositions, fibers and articles produced therefrom, and methods for producing same |
US10214643B2 (en) | 2008-09-30 | 2019-02-26 | Columbia Insurance Company | Recycled polyethylene terephthalate compositions, fibers and articles produced therefrom, and methods for producing same |
US10920071B2 (en) | 2008-09-30 | 2021-02-16 | Columbia Insurance Company | Recycled polyethylene terephthalate compositions, fibers and articles produced therefrom, and methods for producing same |
US10920072B2 (en) | 2008-09-30 | 2021-02-16 | Columbia Insurance Company | Recycled polyethylene terephthalate compositions, fibers and articles produced therefrom, and methods for producing same |
US10391053B2 (en) | 2010-07-19 | 2019-08-27 | Biogen Chesapeake Llc | Methods of intravenous administration of glyburide |
EP2595633A4 (en) * | 2010-07-19 | 2014-01-22 | Remedy Pharmaceuticals Inc | Methods of intravenous administration of glyburide and other drugs |
EP3586850A1 (en) * | 2010-07-19 | 2020-01-01 | Biogen Chesapeake LLC | Methods of intravenous administration of glyburide and other drugs |
US9254259B2 (en) | 2010-07-19 | 2016-02-09 | Remedy Pharmaceuticals, Inc. | Methods of intravenous administration of glyburide |
US8946293B2 (en) | 2010-07-19 | 2015-02-03 | Remedy Pharmaceuticals, Inc. | Methods of intravenous administration of glyburide and other drugs |
US10786445B2 (en) | 2010-07-19 | 2020-09-29 | Biogen Chesapeake Llc | Methods of intravenous administration of glyburide |
US11559481B2 (en) | 2010-07-19 | 2023-01-24 | Biogen Chesapeake Llc | Methods of intravenous administration of glyburide |
KR101917975B1 (en) * | 2010-07-19 | 2018-11-13 | 바이오젠 체사피크 엘엘씨 | Methods of Intravenous Administration of Glyburide and other Drugs |
US9561176B2 (en) | 2010-07-19 | 2017-02-07 | Remedy Pharmaceuticals, Inc. | Methods of intravenous administration of glyburide |
US10052280B2 (en) | 2010-07-19 | 2018-08-21 | Biogen Chesapeake Llc | Methods of intravenous administration of glyburide |
EP2595633A2 (en) * | 2010-07-19 | 2013-05-29 | Remedy Pharmaceuticals, Inc. | Methods of intravenous administration of glyburide and other drugs |
US11084778B2 (en) | 2012-05-08 | 2021-08-10 | Aeromics, Inc. | Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia |
US11873266B2 (en) | 2012-05-08 | 2024-01-16 | Aeromics, Inc. | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke |
US11071744B2 (en) | 2013-11-06 | 2021-07-27 | Aeromics, Inc. | Prodrug salts |
US10894055B2 (en) | 2013-11-06 | 2021-01-19 | Aeromics, Inc. | Pharmaceutical compositions, methods of making pharmaceutical compositions, and kits comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}4-chlorophenyl dihydrogen phosphate |
US11801254B2 (en) | 2013-11-06 | 2023-10-31 | Aeromics, Inc. | Pharmaceutical compositions and methods of making pharmaceutical compositions comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate |
Also Published As
Publication number | Publication date |
---|---|
CA2583397C (en) | 2013-05-21 |
US10583094B2 (en) | 2020-03-10 |
US20200163902A1 (en) | 2020-05-28 |
WO2006036278A3 (en) | 2007-02-22 |
EP1802313B1 (en) | 2010-11-03 |
EP2382977B1 (en) | 2014-08-06 |
CA2583397A1 (en) | 2006-04-06 |
EP2359832A2 (en) | 2011-08-24 |
AU2005290238A1 (en) | 2006-04-06 |
CN101043891A (en) | 2007-09-26 |
EP1802313A2 (en) | 2007-07-04 |
CN101217962A (en) | 2008-07-09 |
IL181740A0 (en) | 2008-04-13 |
WO2006036278A8 (en) | 2007-05-18 |
ATE486606T1 (en) | 2010-11-15 |
US20090130083A1 (en) | 2009-05-21 |
CN101217962B (en) | 2011-05-11 |
EP2382977A1 (en) | 2011-11-02 |
JP2008513447A (en) | 2008-05-01 |
EP2359832A3 (en) | 2011-11-23 |
DE602005024597D1 (en) | 2010-12-16 |
JP5307397B2 (en) | 2013-10-02 |
JP2012017346A (en) | 2012-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200163902A1 (en) | THERAPEUTIC AGENTS TARGETING THE NCCa-ATP CHANNEL AND METHODS OF USE THEREOF | |
US20170112860A1 (en) | Novel non-selective cation channel in neuronal cells and methods for treating brain swelling | |
US7872048B2 (en) | Methods for treating spinal cord injury with a compound that inhibits a NCCa-ATP channel | |
JP2008513447A5 (en) | ||
US20210113589A1 (en) | Targeting ncca-atp channel for organ protection following ischemic episode | |
Simard et al. | Therapeutic methods that target the NC CA-ATP channel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005290238 Country of ref document: AU Ref document number: 181740 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2583397 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007532321 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005805849 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2893/DELNP/2007 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2005290238 Country of ref document: AU Date of ref document: 20050725 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580035902.8 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005290238 Country of ref document: AU |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 2005805849 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11574793 Country of ref document: US |